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Abstract 
 
Background: Whole breast radiotherapy (RT) is the standard treatment for breast cancer 
following breast-conserving surgery. Evidence shows that tumour recurrences occur near the 
original cancer: the tumour bed. New treatment developments include increasing dose to the 
tumour bed during whole breast RT (synchronous integrated boost) and only irradiating the 
region around the tumour bed, for patients at high and low risk of tumour recurrence 
respectively. Currently, standard imaging uses bony anatomy to ensure accurate delivery of 
whole breast RT. It is debatable whether more targeted treatments such as synchronous 
integrated boost and partial breast RT require image-guided radiotherapy focussing on 
implanted tumour bed clips (clip-based IGRT). 
 
Objectives: Primary - to compare accuracy of patient set-up using standard imaging versus 
clip-based IGRT. Secondary objectives – comparison of standard imaging with clip-based 
IGRT for (i) adequate RT safety margins around the tumour bed to avoid geographical miss 
(ii) volume of breast tissue irradiated around tumour bed, (iii) estimated breast toxicity 
following development of a normal tissue control probability model, and (iv) time taken for 
each imaging method. 
 
Design: Multi-centre observational study embedded within a national randomised trial: 
IMPORT (Intensity Modulated Partial Organ Radiotherapy) HIGH testing synchronous 
integrated boost and using clip-based IGRT. 
 
Setting: Five radiotherapy departments, participating in IMPORT HIGH. 
 
Participants: 218 patients receiving breast radiotherapy within IMPORT HIGH  
 
Interventions: There was no direct intervention in patients‟ treatment. Experimental and 
control intervention were clip-based IGRT and standard imaging, respectively. IMPORT 
HIGH patients received clip-based IGRT as routine; standard imaging data was obtained 
from IGRT images. 
 
Main outcome measures: As per objectives. 
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Results: The primary outcome of overall mean difference in clip-based IGRT and standard 
imaging using daily set-up errors was 2mm to 2.6 mm (p<0.001). Heterogeneity testing 
between centres found a statistically significant difference in set-up errors at one centre. For 4 
centres (179 patients), clip-based IGRT gave a mean decrease in the systematic set-up error 
of between 1 and 2 mm compared to standard imaging.  Secondary outcomes were as 
follows: clip-based IGRT and standard imaging safety margins were less than 5mm, and 8 
mm, respectively.  Using clip-based IGRT, the median volume of tissue receiving 95% of 
prescribed boost dose was decreased by 29 cm
3
 (range 11-193 cm
3
) when compared with 
standard imaging. Difference in median time required to perform clip-based IGRT compared 
to standard imaging was X-ray imaging technique dependent (range 8 s to 76 s). It was not 
possible to estimate differences in breast toxicity as the normal tissue control probability 
model indicated that for breast fibrosis, maximum radiotherapy dose is more important then 
volume of tissue irradiated. 
 
Conclusions and implications for clinical practice: Margins less than 8 mm cannot be used 
safely without clip-based IGRT for patients receiving concomitant tumour bed boost as there 
is a risk of geographical miss of the tumour bed being treated within the high dose region. In 
principle, smaller but accurately placed margins may influence local control and toxicity 
rates, but this needs to be evaluated from mature clinical trial data in the future.  
 
 [499 words] 
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Scientific Summary  
 
Background 
The role of breast radiotherapy after breast conserving surgery is well established with the 
2005 systematic overview of the Early Breast Cancer Trialists Collaborative Group 
demonstrating a 70% proportional reduction in local tumour recurrence risk following 
radiotherapy for patients treated with breast conserving surgery for early stage breast cancer. 
 
A wealth of evidence confirms that most recurrences occur close to the primary tumour: in 
the region referred to as the tumour bed. For this reason a higher radiotherapy dose may be 
given to the tumour bed compared to the rest of the breast. This extra tumour bed “boost” 
typically reduces local relapse risk by 50%, at the expense of a 30% increase in the risk of 
moderate/severe breast fibrosis and is usually given after whole breast radiotherapy. New 
treatment developments include increasing dose to the tumour bed during whole breast 
radiotherapy (synchronous integrated boost) and simply irradiating the region around the 
tumour bed (partial breast radiotherapy), for patients at high and low risk of tumour 
recurrence respectively.  
 
Currently, standard imaging uses bony anatomy to ensure accurate delivery of whole breast 
radiotherapy. In addition, a relatively wide safety margin of normal tissue is added to the 
breast to account for uncertainties in its position on each day of treatment. New imaging 
techniques use titanium clips implanted in the tumour bed during surgery, which are imaged 
with x-rays during treatment. This is called clip-based image guided radiotherapy (IGRT) and 
has been used in conjunction with synchronous integrated boost and partial breast 
radiotherapy as it is perceived to locate the tumour bed more accurately than standard 
imaging. This perception has led to the use of smaller safety margins around the tumour bed 
under the premise that the smaller volume irradiated will reduce late normal tissue toxicity 
(mainly fibrosis) and facilitate dose escalation, which may reduce tumour recurrence. Despite 
this shift in breast radiotherapy practice, two questions remain largely unanswered. Firstly, 
what is the accuracy of clip-based IGRT compared to standard imaging? Secondly, if clip-
based IGRT irradiates a smaller volume of normal breast tissue around the tumour bed, can 
we predict how this would reduce side effects?  
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The UK IMPORT HIGH trial provided a unique opportunity to answer the above questions 
and is led by members of the group involved in this study. It is a randomised trial of 
radiotherapy dose escalation using a synchronous integrated boost, in women at higher than 
average risk of local cancer recurrence after breast conserving surgery. The programme of 
work presented in this report is a sub-study of the IMPORT HIGH trial. There was no 
intervention in patients‟ treatment: IMPORT HIGH patients received clip-based IGRT as 
routine; standard imaging data was obtained from IGRT images. This novel sub-study design 
allows direct comparison of clip-based IGRT with standard imaging, but does not pose the 
ethical dilemma of randomising patients to potentially less accurate imaging for synchronous 
integrated boost radiotherapy. 
 
Objectives 
The primary objective was: 
 To compare the spatial accuracy of breast radiotherapy based on imaging i) titanium 
surgical clips implanted in the tumour bed (clip-based IGRT) and ii) bony anatomy 
and lung position during curative radiotherapy for early breast cancer (standard 
imaging).  
 
Secondary objectives were: 
Comparison of standard imaging with clip-based IGRT for:  
(i) Adequate RT safety margins around the tumour bed to avoid geographical miss  
(ii) Volume of breast tissue irradiated around tumour bed  
(iii)  Estimated breast toxicity following development of a normal tissue control 
probability model  
(iv)  Time taken for each imaging method 
 
Methods 
This project was a staged programme of work with five main studies. These may be split into 
two sets. The first set involved study of the evidence for a dose volume effect in breast 
radiotherapy. The second set involved an analysis of the effects of clip-based IGRT on 
treatment margins. 
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The set of studies to evaluate evidence for a dose volume effect in breast radiotherapy had 
two component studies. The first was a review of the published literature and the second was 
a quantitative analysis of dose volume effect for breast tissue. 
 
The literature review evaluated evidence from a range of radiotherapy studies. These 
included randomised trials evaluating a boost to the tumour bed versus no boost, with the 
boost delivered via a range of modalities and approaches, including brachytherapy, cobalt-60, 
inter-operative irradiation, electrons and photons. A second area of analysis of the literature 
was the evidence from studies of partial breast irradiation, which is a mode of treatment with 
current clinical and research activity. A third area of analysis was evidence from breast 
fractionation studies. 
 
In the second study, data from two large randomised trials were analysed: the Cambridge 
IMRT (intensity modulated radiotherapy) trial and the EORTC 22881-10882 “boost versus 
no boost” trial. The Cambridge trial was a single centre study, which recruited 1145 patients 
with stage T1-T3N0-1M0 invasive breast cancer or ductal carcinoma in situ. Patients 
received whole breast radiotherapy, followed by an electron boost to the tumour bed in 
selected cases (n=728). Breast fibrosis was assessed at 2 and 5 years after completion of 
radiotherapy. The EORTC study was a multi-centre trial that recruited 5569 patients with 
stage T1-T2N0-1M0 invasive breast cancer. Patients received whole breast radiotherapy and 
were randomised to three boost levels: no boost (n=2657), ii) 10 Gy boost (n=126), iii) 16 Gy 
boost (n=2661), and iv) 26 Gy boost (n=125). Breast fibrosis was assessed clinically at 
follow up. The relationship between partial breast volume irradiated to high dose and 
probability of moderate or severe fibrosis was fitted using two standard NTCP (normal tissue 
complication probability) models: the Lyman Kutcher Burman (LKB) and Niemierko 
models. These models use three parameters to describe the dose response: the uniform dose 
to the whole breast to produce 50% complication probability, the steepness of the dose 
response and the volume effect. 
 
The second set of studies examined the effects of clip-based IGRT. It was carried out as a 
sub-study of the IMPORT HIGH national trial. The clip-based IGRT approach used in 
IMPORT trial was the use of titanium surgical clips implanted at the time of breast 
conserving surgery and imaged using x-rays. The first study compared the clip-based IGRT 
method with two other approaches: the use of x-ray imaging of bony anatomy (standard 
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imaging) and the use of laser-based set-up using skin markers (no imaging). In the first 
analysis the set-up accuracy of these methods was analysed and the resulting safety margins 
for set-up error needed were determined. The time required to perform image matching of 
clips and bony anatomy was also measured and recorded. A second study evaluated the 
patient and treatment characteristics that influenced the resulting set-up errors. The third 
study evaluated the effects of the margins required for the three set-up methods on the 
radiotherapy planning of the patient‟s treatment. 
 
218 patients recruited by five centres to the IMPORT HIGH trial contributed to this study. 
The centres used a range of imaging methods to visualise the titanium clips and bony 
anatomy. Centre A used kV cone-beam CT (n=79), B used megavoltage-energy CT (n=40) 
and C, D and E used 2D kV planar imaging (n=39, 30 and 30, respectively). 
 
Patient random and systematic set-up errors were measured for bony anatomy and clip-based 
IGRT. The differences between the two measurement sets were used to generate delta errors 
which described the extra uncertainty produced by the use of bony anatomy matching in the 
absence of clip-based IGRT. Differences in set-up errors, delta errors and times between 
centres, imaging modalities and imaging protocols were investigated. Population random and 
systematic set-up errors was determined and used to generate the necessary margins for error 
to achieve target coverage, using standard margin formulae and for a variety of image 
verification protocols.  
 
Patient and treatment characteristics that influence set-up accuracy were studied using patient 
characteristics of position of the tumour bed and breast volume. Surgery characteristics 
included seroma visibility, surgery closing technique, number of clips and clip position. 
Radiotherapy characteristics included IMPORT HIGH trial arm, time between surgery and 
chemotherapy and time between chemotherapy and radiotherapy.  
 
The effects of the different safety margins using clip-based IGRT and standard imaging were 
studied by re-planning 60 patients from the IMPORT HIGH trial. Treatment plans were 
generated for two planning target volume (PTV) margins: 5 mm (achievable with clip-based 
IGRT) and 8 mm (required for bony anatomy based verification). Two types of plan were 
generated: 30 patients were planned using a sequential, conformal photon boost to the tumour 
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bed and 30 using the simultaneous integrated boost technique. The plans were generated to fit 
the dose constraints required by the IMPORT HIGH trial. 
 
Results 
In the literature review, one of the strongest pieces of evidence for a dose-volume effect was 
from a study by Borger et al using low dose iridium implants. This study found evidence that 
for every 100 cm
3
 increase in the volume of the boost region, the risk of fibrosis increased by 
a factor of four and that a two-fold increase in boost volume results in an 11% reduction in 
the normal tissue tolerance dose. Other studies supporting volume effect for breast tissue 
included trials comparing brachytherapy based partial breast irradiation (PBI) and intra-
operative radiotherapy (IORT) with whole breast irradiation. The brachytherapy and intra-
operative dose distribution can differ from the external beam radiotherapy and therefore, it is 
unclear whether these results can be extrapolated to external beam techniques. There is some 
evidence to support volume effect using external beam techniques. The Royal Marsden 
Gloucester trial used an electron boost and showed that for every Gy increase in boost dose, 
the risk of moderate to severe breast induration increases by 1%. In comparison, a 1Gy 
increase to the whole breast can increase the risk of moderate-severe breast induration by 3%, 
indicating a dose-volume effect. Two large studies, IMPORT Low and Danish Breast Cancer 
Cooperative Group trial used external beam radiotherapy for partial breast irradiation and will 
provide more robust data on dose-volume effect in the near future.  
 
Individual patient data of 5856 patients from the Cambridge trial and EORTC trial was used 
to develop the normal tissue complication probability (NTCP) model of breast fibrosis. The 
best fit for the Niemierko model gave a value for the biologically equivalent uniform dose 
(BEUD) dose to the whole breast which produces a 50% complication rate of 136.4 Gy. The 
parameter describing the steepness of the dose response was γ50 = 0.9 and the parameter for 
the volume response was n = 0.011. The best fit for the LKB model was (BEUD50=132 Gy, 
m = 0.35 and n = 0.012). The n parameter describing the volume effect ranges between 0 (for 
no volume effect) and 1 (for a strong volume effect). Hence, these results, from both models 
strongly imply that the risk of moderate or severe breast fibrosis is mainly associated with 
radiotherapy dose and that the change in volume of tissue irradiated does not change the risk 
of breast fibrosis.  These results were validated on an independent dataset from the START 
trial. One of the secondary objectives of the programme was to estimate the reduced risk of 
late adverse effects resulting from the smaller tissue volume irradiated. However, based on 
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the results of “no volume effect”, it was not possible to predict a reduction in risk of breast 
fibrosis if a smaller tissue volume is irradiated. Clearly, any model has limitations and the 
mature results from the clinical trials addressing this question are awaited. 
 
The primary research objective of this study was to compare the accuracy of clip-based IGRT 
and standard imaging using bony anatomy. The random and systematic set-up errors for bony 
anatomy and clip-based IGRT were found to be 3 mm averaged over the five centres, with no 
strong evidence for differences between the centres. The delta errors (difference between 
clips and bony anatomy) were found to be between 2 and 3 mm. The margin formulae 
showed that the use of no imaging (i.e. laser-based set-up) requires a PTV margin of 8-10 
mm, the use of standard imaging allows this to be reduced to 7-9 mm and the use of clip-
based IGRT with a suitable verification protocol allows the margin to be reduced to 4-5 mm. 
The time taken to perform clip match was quicker than bony anatomy match using 2D-KV 
technique, but not when using cone beam CT imaging (secondary objective). 
 
For the study of patient, surgery and radiotherapy characteristics that influence set-up errors, 
laser-based set-up (no imaging) was found to be significantly influenced by breast volume, 
seroma visibility and surgical closing technique. Bony anatomy (standard imaging) based set-
up was found to influenced by both breast volume and tumour bed axial position.  
 
The results of the re-planning study showed that the reduced margins that were achievable 
with clip-based IGRT compared to standard imaging (5mm versus 8mm) led to a reduction of 
29 cm
3
 (range 11 – 193 cm3) in the volume of breast tissue receiving a high dose. Using clip-
based IGRT margin (5mm), 56 of the 60 cases met all the IMPORT High treatment planning 
criteria. Using standard imaging margin (8mm), four sequential boost plans and 10 
concomitant boost plans breached mandatory planning constraints. The use of smaller PTV 
margins with clip-based IGRT also allowed a small reduction in the radiotherapy dose to the 
contralateral breast, heart and lung. 
 
Conclusions and implications for clinical practice 
This research demonstrates the benefits of clip-based IGRT over standard imaging, with a 
reduction in PTV margins. Margins less than 8 mm cannot be safely used without clip-based 
IGRT for patients receiving concomitant tumour bed boost as there is a risk of geographical 
miss of the tumour bed being treated within the high dose region.  
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The existing literature suggests a volume effect for breast tissue, but our normal tissue 
complication probability (NTCP) model could not demonstrate a volume effect for breast 
fibrosis.  We anticipate mature results from the ongoing clinical trials to provide a definitive 
answer. In principle, these smaller, but accurately placed margins may also influence local 
control rates, but again this needs to be evaluated from mature clinical trial data in the future.  
 
 
[2344 words] 
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Plain English Summary 
 
Whole breast radiotherapy is the standard treatment for breast cancer following breast-
conserving surgery (lumpectomy). Cancer recurrences are most likely to occur near the 
original cancer: the tumour bed. A new technique aims to reduce recurrence by delivering a 
higher dose to the tumour bed (“boost”) during whole breast radiotherapy. Currently, X-rays 
of the ribcage (standard imaging) are used to ensure accurate delivery of breast radiotherapy. 
Newer imaging using surgical clips within the tumour bed (clip-based imaging) may be 
preferable for boost radiotherapy. 
 
The main objective was to compare accuracy of radiotherapy boost with standard and clip-
based imaging. The bigger “safety margin” required around the tumour bed was calculated 
and a mathematical model was constructed to estimate whether the extra volume irradiated 
caused more side effects. 218 patients receiving breast radiotherapy within a national breast 
boost trial were studied: all had clip-based imaging, but standard images of the ribcage were 
available for comparison. 
 
Results show that clip-based imaging is more accurate than standard imaging for boost 
radiotherapy and safety margins are 5mm and 8 mm, respectively.  The volume of breast 
tissue irradiated decreased by 29 cm
3
 (range 11-193 cm
3
) using clip-based imaging, but 
estimation of side effects was not possible using the model. 
 
In conclusion, margins less than 8 mm cannot be used safely without clip-based imaging for 
patients receiving boost radiotherapy as the higher dose boost treatment may “miss” the 
tumour bed. Smaller margins may reduce both cancer recurrence and side effects, but long-
term results from on-going trials are needed.  
 
[250 words] 
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Chapter 1 - Introduction 
 
Structure of this report 
 
The work in this report is based on a sub-study of a national randomised controlled trial 
(RCT) called IMPORT HIGH (intensity modulated and partial organ radiotherapy trial – 
higher risk patient group) (CRUK/06/003). This trial was funded by Cancer Research UK 
under grant number (C1491/A16831) The sub-study is known as IMPORT-IGRT (intensity 
modulated and partial organ radiotherapy trial – image guided radiotherapy study). 
 
The work described is a staged EME (Efficacy and Mechanism Evaluation programme) study 
and hence the structure of the report reflects the stages of the programme. 
 
The report starts with a review of the background to the problem of target localisation in 
breast radiotherapy and the expected advantages of image guided radiotherapy to solve 
various aspects of the problem. The research objectives are listed at the end of this first 
chapter. 
 
Subsequent chapters then address each of the components of the study. These generally fall 
into two groups: i) radiobiological side-effects of radiotherapy on normal breast tissue and ii) 
a study of the role of image guidance to improve treatment accuracy, reduce margins for 
error, and consequently reduce effects on normal tissue. Two chapters discuss radiobiology. 
Chapter 2 is a critical review of the literature on the relationship between irradiated volume 
of breast tissue and late breast tissue complications and chapter 3 is the analysis of pooled 
results from two randomised trials. Three chapters discuss aspects of the role of clip-based 
IGRT. The first of these, chapter 4, presents a comparison of standard imaging and clip-based 
IGRT for 5 centres participating in the IMPORT HIGH trial. Chapter 5 presents an analysis 
of factors that influence the relationship between set-up errors and margins generated using 
visual set-up, standard imaging and IGRT. In this analysis, clip-based IGRT is taken as the 
gold standard. Chapter 6 presents an analysis of the volume of tissue spared high dose 
irradiation using IGRT compared with standard imaging approaches. 
 
The final chapter summarises the findings of this project and presents the key conclusions 
from this research programme. 
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Background 
 
Radical RT following breast conserving surgery (BCS) is a proven alternative to mastectomy 
for a majority of women developing breast cancer. The success of the treatment was 
highlighted in the 2005 systematic overview of the Early Breast Cancer Trialists 
Collaborative Group (EBCTCG)
1
 which showed a 70% proportional reduction in local 
tumour recurrence risk following radiotherapy for patients treated with BCS for early stage 
breast cancer. 
 
For every 100 women treated, radiotherapy prevents 20 local cancer relapses in the breast and 
5 cancer-related deaths 10 years post-treatment
1
. Approximately 30,000 women are given 
radiotherapy for early breast cancer in the UK every year, resulting in the prevention of 6,000 
local tumour relapses and 1,500 deaths from cancer. An estimated 1,500 local tumour 
relapses occur despite radiotherapy, with a disproportionate number affecting women below 
fifty years old, who have three times the risk of local relapse risk than  women in older age 
groups
2
. A wealth of evidence confirms that most relapses occur close to the primary tumour: 
in the region referred to as the tumour bed
3
. This is the reason for giving a higher dose of 
radiotherapy to the tumour bed than to the rest of the breast. This extra dose to the tumour 
bed is called the boost and typically reduces local relapse risk by 50% at the expense of a 
30% increase in moderate or severe hardening of breast tissue due to fibrosis
2,4
. Currently 
used protocols require a wide margin of healthy tissue to be added around the tumour bed to 
compensate for substantial (5-10 mm) variations in the patient position from one day of 
treatment to the next, which consequently limits the radiation dose that can be safely 
delivered. The challenge is to safely reduce the volume of healthy tissue included in the boost 
treatment in order to reduce the risk of late complications with the consequence of allowing 
dose escalation to be done safely and potentially higher cure rates. The hypothesis tested in 
this programme was that modern radiotherapy technology (including treatment machines 
equipped with on-line x-ray imaging facilities that can monitor the position of internal organs 
relative to the treatment beam, accurately) allows a substantial reduction in the safety margin 
around the tumour bed, thus reducing both exposure of healthy tissue and chronic 
complication with the inherent possibility of safe dose escalation. 
 
The UK IMPORT HIGH trial provided a unique opportunity to test this novel approach. 
IMPORT HIGH is led by members of the group involved in this study. It is a randomised trial 
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of radiotherapy dose escalation in women at higher than average risk of local cancer 
recurrence after surgery. The two main challenges for this current project are i) direct 
measurement of the magnitude of tumour bed margin reduction and therefore tumour bed 
boost volume reduction achieved by tumour bed imaging and ii) estimation of the reduction 
in rates of moderate and severe fibrosis (breast hardening). The success of this project was 
judged based on these two challenges. 
  
Radiotherapy delivery for breast cancer is a two-stage process. Firstly the patient has a CT 
(computed tomography) scan of her breast and chest region. During this scan the patient is 
lying in a comfortable position that is reproducible during subsequent visits for treatment. 
The CT dataset obtained is a basis for planning the treatment. This involves finding the 
optimum method of targeting the therapeutic radiation beam to deliver the desired dose 
distribution. Once the treatment plan is available, the patient commences a treatment 
programme consisting of a sequence of daily treatment visits, called fractions, typically over 
a period of 3 weeks. The positioning of the patient during these fractions is the same as that 
for the planning CT scan. This is achieved using the positioning of tattoos on the patient‟s 
skin surface relative to the treatment beam (with the help of a set of laser lights that are fixed 
relative to the position of the treatment beam).  
 
The treatment beam is a high-energy x-ray beam. This is chosen as it penetrates well through 
tissue and interacts fairly uniformly with various tissue types (e.g. fat and muscle). A 
consequence of this is that the radiation dose distribution is well behaved in the different 
tissue types but the high energy x-ray beam is not optimal for imaging, which ideally requires 
substantial differences in how the beam interacts with different tissues. During most standard 
approaches to treatment, images are acquired using the high energy x-ray beam, but these 
show only tissues whose density is greatly different to soft tissues, e.g. the ribs and lungs,  
not the soft tissues of the breast in the region where the tumour bed is. The images are 
compared with the planning CT images, collected before treatment, to identify discrepancies 
in the positioning of ribs and lung within the beam, referred to as set-up errors. If set-up 
errors are found to exceed predefined limits, then the patient is re-positioned, before the next 
treatment fraction is delivered. This repositioning is of the order of several mm. It is small on 
the scale of the human body but significant for radiotherapy accuracy. A major problem with 
this approach is that the positions of the lungs and ribs do not necessarily predict with 
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sufficient accuracy the location of the tumour bed. As a consequence wide margins of healthy 
tissue need to be added to the tumour bed boost volume. 
 
Standard practice uses the high energy x-ray beam produced by the treatment machine to 
identify the position of the ribs and lungs within the beam. The high energy x-rays are too 
penetrating to show the soft tissues of the breast, also the tumour bed can move more than a 
centimetre relative to the bony anatomy and lungs. The inability to directly visualise the 
tumour bed means that its position cannot be measured directly, requiring a safety margin to 
avoid geometric miss and hence the exposure of a volume of normal breast tissue to higher 
doses than needed. The volume of tissue including this safety margin is known as the tumour 
bed boost volume.  The need for this safety margin can substantially increase the volume of 
tissue irradiated. 
 
This larger volume of healthy tissue irradiated around the tumour bed also places limits on 
the total dose that can be safely delivered. The hypothesis under test in this study is that if the 
tumour bed is imaged directly during treatment, the volume of healthy tissue in the tumour 
bed boost volume can be reduced, leading to a smaller volume of healthy tissue irradiated and 
hence to fewer treatment complications. An alternatively strategy, in women at highest risk of 
local recurrence, is to allow safe dose escalation to the tumour bed, with expected better local 
cancer cure rates. Before justifying these expectations, a simple surgical technique will be 
described that has enabled the tumour bed to be imaged directly on each day of a patient‟s 
radiotherapy. 
 
As part of the enabling infrastructure for the IMPORT HIGH study we have asked UK breast 
surgeons to attach standard titanium surgical clips to the walls of the tumour excision cavity. 
This accurately demarks the position of the tumour bed. Pilot work was undertaken in 
preparation for the IMPORT HIGH trial and as a consequence clips are now recommended 
for all patients undergoing breast conservation surgery by the British Association of Surgical 
Oncology
5
. The key advantage of this approach is that surgical clips can be visualised 
directly using the low energy x-ray facility on the treatment machine. Furthermore it has been 
confirmed that boost treatments verified using the position of clips are more accurate than 
those only relying on imaging of the positioning of the ribs and lungs
6
. 
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Discrepancies between the expected, planned positions of the surgical clips (based on the 
planning x-ray CT scan performed before the treatment) and the actual positions of the clips 
(based on imaging on the treatment machine) are corrected using small movements of the 
patient, of typically a few millimetres. The use of x-ray imaging of surgical clips to verify 
radiotherapy accuracy in real-time, i.e. immediately before each treatment fraction is given, is 
referred to as clip-based image guided radiotherapy (clip-based IGRT). The pilot study for 
the IMPORT HIGH trial suggests that clip-based IGRT is likely to allow smaller safety 
margins of healthy breast tissue around the tumour bed
7
. 
 
If the standard imaging method is used to verify the accuracy of the patient‟s treatment no 
information about the tumour bed is available. In a comparison of clip-based IGRT and bony 
anatomy set-up (i.e. the standard imaging approach), an additional safety margin of 4.5 - 5.5 
mm was needed for standard imaging
8
. Another study found the set-up error to be on average 
4mm (with 3 mm variation at 1 standard deviation) greater when using standard set-up 
compared to clip-based IGRT
9
. In a recent review of the growing literature reporting 
significant changes in the size and position of the tumour bed, Kim et al.
10
 highlighted the 
fact that clinical factors such as the time between surgery and chemotherapy and the planning 
CT scan influence the size of the change in the tumour bed that occurs during treatment. If 
large changes occur then standard imaging is unable to detect this and consequently errors in 
patient positioning will increase in the presence of such changes. For any subset of patients, 
for whom there are clinical factors that result in large changes in the size and position of the 
tumour bed we would expect that the inaccuracy of standard imaging compared to IGRT 
would be greater and subsequently greater margins would need to be applied to ensure good 
target coverage. An example of this is the sub-set of patients who receive chemotherapy and 
consequently have a longer time interval between surgery and the start of radiotherapy. A 5 
mm safety margin is added around the tumour bed in the IMPORT HIGH trial, compared to a 
10 mm margin when standard set-up is used. In summary, reducing margins around the 
tumour bed translate into smaller volumes exposed to high doses and fewer expected late side 
effects, such as hardness and tenderness of the breast. Clinical evidence justifying this 
expectation is now discussed. 
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Risks and benefits in breast radiotherapy 
 
The dose responses for tumour control and normal tissue damage in radiotherapy are long 
established and well understood. In the UK Standardisation of Breast Radiotherapy (START) 
trials (conducted by members of the IMPORT HIGH trial group and the group undertaking 
this study) physical morbidity was defined in terms of breast shrinkage, distortion and 
fibrosis. This was scored by i) independent expert observers using serial clinical photographs, 
ii) examination by physicians in the clinic and iii) by patient self-assessment at regular time-
points over 5 years of follow up
4,11
. We reported one third of women with minor or marked 
change in photographic breast appearance (in terms of shrinkage and distortion). These 
chronic effects increase in incidence and severity even after 5 years post radiotherapy. The 
photographic changes were in accordance with prospective patient self-assessments of 
adverse effects, including moderate or marked change in skin appearance (reported by around 
30% of patients), breast hardness (over 40%), and breast shrinkage (over 20%). A study of 
254 patients undergoing breast conserving surgery and radiotherapy reported that physical 
changes in breast tissue had a marked bearing on subsequent psychological outcome
12
. 
Patients completed questionnaires assessing satisfaction with treatment outcome and scored 
psychosocial morbidity using the Hospital Anxiety and Depression (HAD) scale, the Body 
Image questionnaire and the Rosenberg Self-esteem scale. There was a strong association 
between the breast appearance and levels of anxiety (r = -0.81, P <0.001), depression (r = -
0.7, P <0.001), body image (r = -0.4, P <0.001), sexuality (chi
2 
= 22, P = 0.001) and self-
esteem (r = -0.64, P <0.001). Similar findings were recorded in the START trials, which 
detected a significant association between body image and anxiety and depression
13
.  
 
The START trials confirmed a steep dose response for radiotherapy complications: a 10% 
increase in whole breast radiotherapy dose doubled the rate of late adverse effects. A clear 
volume response was also observed, with the adverse effect of radiotherapy on normal tissue 
varying according to the volume of tissue irradiated. The magnitude of the volume response 
can be generated in different ways, most directly by comparing the outcome of the same dose 
schedule delivered to different partial volumes of breast tissue. In a retrospective study of a 
radiotherapy boost dose delivered using radioactive implants in 404 patients, a 4-fold 
increase in risk of breast fibrosis (hardness) was reported for each 100cm
3
 increment in boost 
volume, suggesting a very steep volume response
14
 and confirming the desirability to review 
the evidence for a volume effect. 
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These findings are consistent with univariate analysis of 364 patients randomised to a 
radiotherapy tumour bed boost dose after whole breast radiotherapy, which reported a hazard 
ratio for poor cosmesis of 0.45 (95% CI, 0.29 – 0.76) for boost volumes dichotomised to 
below 200 cm
3
 compared to boost volumes above 200 cm
3 15
). Another approach to quantify 
the increased risk of late side-effects is to compare the increased risk of late side-effects after 
a boost dose to the tumour bed compared with the same dose delivered to the whole breast. 
Such an analysis has been performed in 723 patients in the START pilot trial randomised to 
tumour bed boost dose versus no tumour bed boost
14
. Patients randomised to a tumour bed 
boost of 15.5 Gy in 7 fractions had a 17% higher risk of moderate or marked breast hardness 
at 10 years. The same randomised trial compared two dose levels of whole breast 
radiotherapy. The dose of whole breast radiotherapy causing a 17% increased risk of breast 
hardening was estimated to be 4.5 Gy. This value is much lower than the 15.5 Gy that causes 
the same level of breast hardening when given to a boost volume of about 200 cm
3
, 
representing 20-30% of whole breast volume. 
 
From previous work including our own pilot study
7
, we estimated that the margins of a 
conventional tumour bed boost volume can be safely reduced by approximately 5mm in all 
spatial dimensions using IGRT. From our pilot study the average tumour bed boost volume 
required is approximately 70 cm
3
, reduced from 110 cm
3
, a reduction of the total volume of 
the average breast boost dose by approximately 40 cm
3
, and was expected (after Borger et 
al.
14
) to reduce the risk of moderate to severe fibrosis by up to a factor of 1.7.  
 
We considered a randomised trial to be a cumbersome and expensive technology to apply to 
address the problems discussed above. On the other hand, the lack of empirical research data 
justifying the widespread use of clip-based IGRT meant that the necessary resources to 
implement clip-based IGRT in routine clinical practice are not available, and the position was 
that expensive and potentially valuable equipment was often left idle.  
 
Whatever research methodology is used, the preferred primary endpoint should measure 
treatment accuracy. Gains in accuracy can be derived directly (without assumptions) from 
data collected in an ongoing clinical trial that uses clip-based IGRT to verify treatment 
accuracy as part of its technical quality assurance protocol. The IMPORT HIGH trial 
provided a very reliable context in which to test the hypothesis that more accurate treatment 
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verification allows a substantial reduction in the volume of breast tissue exposed to high 
boost doses of radiotherapy. By generating direct estimates of the mean volume of breast 
spared by daily clip-based IGRT, it should be possible to estimate the expected reductions in 
late adverse effects. These estimates were largely based on published results of randomised 
trials conducted by members of our collaboration
4,11,16,17
. A consequence of this is the 
possibility to estimate the degree to which dose could be safely escalated in the group of 
patients at highest risk of local recurrence, and the predicted consequent benefits in terms of 
improved local tumour control.    
 
The study aimed to quantify the benefits of clip-based IGRT using titanium clips in breast 
cancer patients using a study design that did not jeopardise patient care. Accurate tumour bed 
localisation has been shown to be important to ensure the accuracy of whole breast 
radiotherapy
7,18
. Also the results of this study should be applicable for all patients with breast 
cancer, including those prescribed partial breast radiotherapy. Proven, quantified benefit from 
clip-based IGRT for breast cancer patients with higher risk of recurrence would justify the 
routine adoption of clip-based IGRT in all UK centres and hence ensure equity of access and 
optimal treatment for all breast cancer patients. 
 
Research Hypotheses 
 
1. Clip-based IGRT provides more accurate method of locating the tumour bed compared to 
standard imaging.  
2. Clip-based IGRT allows smaller margins compared to standard imaging, which translate 
into less toxicity and improved quality of life for patients.  
 
Research objectives 
 
The primary objective was: 
To compare the spatial accuracy of breast radiotherapy based on imaging i) titanium 
surgical clips implanted in the tumour bed (clip-based IGRT) and ii) bony anatomy 
and lung position during curative radiotherapy for early breast cancer (standard 
imaging).  
 
Secondary objectives were: 
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Comparison of standard imaging with clip-based IGRT for:  
I. Adequate RT safety margins around the tumour bed to avoid geographical miss  
II. Volume of breast tissue irradiated around tumour bed  
III. Estimated breast toxicity following development of a normal tissue control 
probability model  
IV. Time taken for each imaging method 
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Chapter 2 – A critical review of the relationship between irradiated breast volume and 
late breast tissue complications 
 
This chapter describes a critical review of the literature which aimed to understand the quality 
and scope of evidence for the relationship between irradiated breast volume and late breast 
tissue complications. This work supported  a secondary objective of this study, the estimation 
of the reduction in risk of late breast toxicity which results from using clip-based IGRT, and 
helped to inform clinical recommendations based on all study outcomes.   
 
This chapter is based on the peer-refereed scientific journal paper:  
Mukesh M, Harris E, Jena R, Evans P, Coles C, Relationship between irradiated breast 
volume and late normal tissue complications: A systematic review. Radiother Oncol 
2012;104:1-10.   
 
Introduction 
 
In radiotherapy the aim is to deliver a tumoricidal dose for optimal loco-regional control 
whilst maintaining relative sparing of the surrounding normal tissues. Accurate knowledge of 
the tumoricidal and tolerance doses to the various tissues along with the effects of irradiating 
partial volumes of organs (i.e. the dose volume effect) is essential for all types of modern 
radiotherapy, including conformal, IMRT and IGRT. 
 
Emami et al.
19 
pioneered this field with a comprehensive review of the current knowledge of 
radiation tolerance doses for normal tissues. This included quantification of late normal tissue 
complication probability (NTCP) as a function of the volume of the organ irradiated. 
Although this review was informative it was limited by the available data, with most of the 
dose volume data based on interpolated or extrapolated from whole organ data, or based on 
the expert experience of the involved clinicians. Since that work was published, an update on 
the dose volume effect of radiation on the normal tissues has been published in the 
“Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC)” report20. This 
can be utilised in treatment planning to estimate the effect of irradiated volume on tissue 
tolerance
21,22
. 
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For many years, the radiation dose-volume effect for the breast has been exploited in the 
boost treatment for breast cancer patients who are at high risk of recurrence. This involves 
treating a small volume of breast tissue to a higher dose with improved local control 
rates
2,23,24
. More recently, the dose-volume effect has been exploited in trials of Partial Breast 
Irradiation (PBI) for patients at low risk of recurrence. In PBI the irradiated volume is 
confined to the region around the tumour bed and the aim is to reduce toxicity whilst 
maintaining the local control rate. However, there is paucity of published data on the dose-
volume effect of irradiation on breast tissue including the QUANTEC report. 
 
The critical review presented in this chapter of the report evaluates the evidence for a 
relationship between the volume of breast tissue irradiated and late complications rates. 
These complications include cosmesis, breast fibrosis, breast induration and telangiectasia. It 
also explores the evidence for a modest reduction of dose to part of the breast allowing dose 
escalation to the tumour bed, with lower NTCP expected. 
 
Methods 
 
Medline and Embase were used to perform a literature search with the following search 
strategy “Breast neoplasm” AND “radiotherapy OR Irradiation”. This was combined with 
“AND fibrosis”, “AND cosme*”, “AND side effect*”, “AND toxicity”, “AND shrinkage” 
and “AND normal tissue”. The search was than expanded to include related articles and a 
reference list of articles and was conducted from 1
st
 January 1975 up to 1
st
 May  2012.  
 
Impact of boost volume on breast tissue complications 
 
 EORTC 22881-10882 “boost versus no boost” trial (level I evidence) 
In the EORTC “boost versus no boost” trial 5318 patients with early breast cancer were 
randomised between a tumour bed boost of 16 Gy and no boost after whole breast irradiation 
(WBI)
2
. The boost dose was delivered using electrons or tangential photon fields with a daily 
fractionation of 2Gy, or using Ir192 implant at a dose rate of 0.5 Gy per hour. The results 
showed that, at 10 years, the use of tumour bed boost of 16 Gy increased the rates of 
moderate to severe breast fibrosis by 15% (28.1% versus 13.2%; p <0.0001). 251 patients 
with microscopically incomplete tumour excision were also randomised to either a low dose 
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boost of 10 Gy (126 patients) or a high dose boost of 26 Gy (125 patients)
25
. The cumulative 
incidence of moderate/severe fibrosis for low dose and high dose boost at ten years were 
found to be respectively 24% and 54%. Thus dose escalation of 16 Gy to the boost volume in 
the incomplete tumour excision group increased the rates of moderate or severe fibrosis by 
30%, compared with a 15% increase in the complete excision group for the same 16 Gy 
increase in dose.  
 
The boost volume for the complete excision group was tumour bed plus 1.5 cm margin as 
compared to tumour bed plus 3 cm margin in the incomplete tumour excision group. This 
suggests a dose volume relationship for breast tissue, as an increase in irradiated breast 
volume in the incomplete excision group doubled the risk of moderate/severe fibrosis for the 
same dose escalation of 16 Gy. However, it may be the case that the increase risk of breast 
fibrosis is secondary to a combination of larger boost volume and a steeper dose response 
curve as the total dose was increased up to 76 Gy in the incomplete excision group. The trial 
group also reported that on univariate analysis, patients with large boost volume are more 
likely to develop sub-optimal cosmesis at 3 years
15
 and breast fibrosis at 10 years
26
. However, 
boost volume was not a significant variable affecting fibrosis and cosmesis in multivariate 
analysis. 
 
Brachytherapy boost (level IV evidence) 
Borger et. al.
14
 reported on the dose-volume effect of brachytherapy boost for breast fibrosis. 
The patient group was 404 patients who were treated with external beam radiotherapy (50 Gy 
in 2 Gy daily fractions to the whole breast). This was followed by an iridium implant boost 
(dose rate 0.57± 0.11 Gy/hour). Brachytherapy doses fell into three groups: 15 Gy for 101 
patients, 25 Gy for 301 patients and 20 Gy for 2 patients. With a median follow-up period of 
70 months, a four times higher risk of fibrosis was observed for each 100 cm
3
 increase in 
irradiated boost volume, and a tenfold higher risk of fibrosis was observed when the total 
dose exceeded 79 Gy compared to doses below 70 Gy.  
 
In another study from Georgetown University Medical Centre, McRae et al. also reported on 
the relationship between brachytherapy boost volume and soft tissue complication
27
. 
Retrospective brachytherapy plans for 5 patients with radiation induced soft tissue damage 
were compared with 51 patients who did not experience severe complication after WBI 
followed by Iridium-192 boost. The mean boost volume for patients who developed soft 
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tissue damage was significantly higher for all dose levels between 10 Gy and 50 Gy when 
compared to patients with no reported complications (p<0.05), suggesting a relationship 
between volume and NTCP at any dose studied. Similarly, Olivotto et. al.
28
 reported an 
association between the brachytherapy boost volume and late cosmetic outcome for 497 
patients who received WBI (46 to 50 Gy over 4.5 to 5 weeks) followed by a low dose rate 
boost with Iridium-192 to bring the tumour bed dose to 60Gy. At a median follow up of 76 
months, the boost volume boost, measured by the number of Iridium seeds used, was found to 
be a significant factor for fair/poor cosmesis. Patients with <70 seeds had a 15% risk of 
fair/poor cosmesis compared to 38% for patients with ≥100 seeds (p<0.01). The use of a 
greater number of seeds implies a larger volume of irradiated breast tissue, and hence a 
radiation volume effect for cosmesis. Several other single and multi-centre studies have 
reported on the relationship between volume of brachytherapy boost and NTCP risk and are 
summarised in Table 1. 
 
Intra-operative RT (IORT) boost using low energy X-ray (level IV evidence) 
IORT uses low energy x-ray of 50 kV and can be used to deliver a single-fraction, high-dose 
radiation boost to the tumour bed after lumpectomy. Advocates for IORT cite several 
potential advantages of using this approach: including delivery of radiation immediately after 
surgery to prevent tumour cell proliferation; change in cytokines pattern into a less 
stimulating microenvironment, which is expected to reduce the local recurrence rates;  and 
reduced risk of geographical miss
29,30
. 
 
The University of Heidelberg reported on late toxicity data (at 3 years) for 79 cases treated 
with the IORT method
31
. All patients received 20 Gy intra-operative boost using a 50 kV x-
ray set followed by 46-50 Gy in 2Gy daily fraction of WBI with or without supra/infra-
clavicular fossa irradiation. 35% of patients developed grade 2-3 breast fibrosis. They 
observed that size of the applicator used for IORT significantly correlated with late breast 
fibrosis (spearman rank correlation coefficient 0.496, p<0.001). A larger applicator size 
would imply a larger volume of irradiated breast tissue, which in turn would suggest a 
radiation volume effect on late breast tissue toxicity. 
 
Cobalt unit based boost (level IV evidence) 
Dewar et. al. from the Institute Gustave-Roussy reported on cosmetic outcome after breast-
conserving surgery and radiotherapy
32
. 592 patients received WBI (45 Gy in 2.5 Gy per 
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fraction, four times weekly). They were treated using two tangential fields, with each field 
treated on alternate days. This was followed by tumour bed boost of 15Gy in 6 fractions 
using on a cobalt unit. Multivariate analysis showed that in addition to applied dose per 
fraction, the area of field to the tumour bed (>30 cm
3
) was associated with an increased risk 
of fibrosis (p<0.02) and telangiectasia (p<0.01). 
 
 Other boost studies (level IV evidence) 
The Fox Chase Cancer Centre, Philadelphia recently presented a reported on tumour bed 
boost parameters associated with overall cosmesis and fibrosis for a group of 3186 patients 
who were treated at their centre from 1970-2008
33
. All patients received whole breast 
radiotherapy (46-50 Gy) followed by a tumour bed boost of 10-18 Gy using either electrons 
or photons. Median follow-up was 78 months. Smaller boost cut-out size was found to be a 
borderline predictor of excellent cosmesis (p=0.05) and lower risk of breast fibrosis 
(p<0.0001) based on univariate analysis. Neither fibrosis nor cosmesis were found to remain 
significantly associated with higher field size on multivariate analysis. However, no 
information was available on the size of the treated boost volume and no distinction was 
made between physician and patient cosmetic score in their report. 
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First author, Institute 
and radiation technique 
Number of patients 
(median follow up) 
TNM/stage Comments on NTCP assessment Results 
Borger et. al.
14
 
Netherlands Cancer 
Institute 
WBI 50Gy in 25 fractions 
over 5 weeks followed by 
low dose rate Iridium 
implant boost  of 15 Gy 
(101 pts), 25Gy (301 pts) 
and 20Gy (2 pts) 
 
404 patients 
median follow up 70 
months (range 30-133 
months) 
 
Stage 1-2 Four trained physicians scored fibrosis 
by palpating induration in the tumour 
bed. 
Four-scale scoring system: no fibrosis 
= no difference in consistency 
between the two breasts, grade 1 = a 
small difference, grade 2 = a moderate 
difference, grade 3 = a large 
difference. The scores of the four 
investigators were averaged to obtain 
the final result per patient 
Implant volume (100% dose) 
associated with risk of fibrosis 
Odds ratio 4.2 (95% CI 2.3-
8.0) per 100cm
3
 increase in 
boost volume 
 
McRae et al.
27
 
Georgetown University 
Medical centre, 
Washington 
WBI 50Gy in 25 fractions 
over 5 weeks using Cobalt 
followed by low dose rate 
Iridium 192 boost of 20Gy 
56 patients with a 
minimum follow up 
of 2.5 years 
Stage 1-3 Radiation injury to connective tissue 
or fat necrosis requiring prolonged 
medical or surgical management 
Mean boost volume 
significantly higher for all dose 
level between 10Gy and 50Gy 
for patients who developed 
soft tissue damage as compare 
to patients with no reported 
complications (p<0.05) 
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Dewar et al.
32
 
Institut Gustave-Roussy, 
France 
WBI 45 Gy in 2.5Gy per 
fraction using two 
tangential fields followed 
by tumour bed boost of 
15Gy in 6 fractions using 
one to two fields on the 
cobalt unit 
592 patients 
mean follow up 78 
months (standard 
deviation 35 months) 
T1-2 N0-1 Fibrosis and/or telangiectasia of the 
whole breast/the tumour bed graded as 
absent, slight, moderate or severe by 
the radiation oncologist. Cosmetic 
outcome graded as excellent, good, 
fair and poor 
Area of field to the tumour bed 
(>30cm
3
) associated with 
increased risk of fibrosis 
(p<0.02) and telangiectasia 
(p<0.01) on multivariate 
analysis. No relationship 
between cosmesis and area of 
field to the tumour bed 
 
Olivotto et al.
28
 
Joint Center for Radiation 
Therapy, Boston 
WBI 46-50 Gy in 4.5-5 
weeks, followed by low 
dose rate Iridium-192 
boost (10-27 Gy) 
 
497/593 with 
Iridium- 192 boost 
Median follow up 76 
months (range 37-186 
months) 
 
 
T1-2 N0-1 Overall cosmesis scored as excellent, 
good, fair or poor by the physician. 
Excellent if treated breast looked the 
same as the opposite breast, good if 
minimal but identifiable effects of 
radiation, fair when significant effects 
of radiation and a  poor if severe 
normal tissue sequelae 
Boost volume measured by 
number of Ir-192 seeds 
associated with increased risk 
of fair/poor cosmesis 
(p<0.0001 for trend) 
 
Clarke et. al.
34
 
Paul A. Bissinger 
Memorial Center for 
64/78 patients with 
Iridium 192 boost 
Median follow up 
Stage1-2 Cosmetic result scored as excellent 
(treated breast looked the same as the 
opposite breast), satisfactory (mild to 
6% patients developed 
moderate/severe fibrosis with 
no correlation between fibrosis 
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Radiation Therapy, 
Stanford 
WBI 45-55Gy in 1.8-2.5 
Gy per fraction followed 
by  low dose rate Iridium- 
192 boost (18-25 Gy) 
 
42months (range 30-
120 months) 
 
 
moderate breast asymmetry with < l/3 
volume loss secondary to surgery or 
retraction from fibrosis) or 
unsatisfactory (marked breast 
asymmetry or severe fibrosis with 
>1/3 volume loss). 
Breast fibrosis scored as mild, 
moderate or severe. 
and implanted boost volume. 
Surgical factors like poorly 
planned excision scar and large 
volume excision main factors 
for unsatisfactory cosmesis. 
 
Wazer et. al.
35
 
Tufts University School of 
Medicine, Boston 
WBI 50 to 50.4Gy at 1.8-
2Gy per fraction followed 
by  low dose rate Iridium-
192 boost of 20Gy 
127 patients  
Median follow up 80 
months (standard 
deviation 34 months) 
Stage1-2 Cosmetic score scored by two separate 
examiners as excellent = perfect 
symmetry and no visible distortion, 
good = slight distortion, visible 
telangiectasia or absent nipple-areolar 
complex, fair = moderate distortion, 
hyper pigmentation, prominent skin 
retraction, oedema or telangiectasia 
and poor = marked distortion, oedema, 
fibrosis, severe hyper-pigmentation. 
The lowest score was used 
No correlation between 
implant volume and cosmetic 
score. 
Wronczewska et. al.
36
 
Nicolaus Copernicus 
54 patients 
Mean follow up 65 
 Cosmesis and breast fibrosis assessed 
by two doctors independently and 
Boost volume receiving 100% 
(V100) was significantly 
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University, Poland 
WBI 50-50.4Gy in 1-8-
2Gy fraction followed by 
high dose rate Iridium-192 
boost of 5-20Gy 
months (range 41-89 
months) 
compared to the contralateral breast associated with risk of breast 
fibrosis (p=0.0236) 
 
Table 1: Effect of brachytherapy boost volume on NTCP. 
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Partial breast irradiation studies 
 
WBI is considered the current standard of care following breast-conserving surgery and in the 
last decade, PBI has been explored as an alternative treatment to WBI in low risk patients. 
PBI involves irradiation of the volume of breast tissue around the tumour bed and is currently 
under investigation in several randomised phase II and III trials (shown in Table 2). This 
treatment approach is based on the rationale that the majority of local recurrences are located 
close to the area of surgical resection/the index quadrant, also the foci of breast disease 
outside the index quadrant are often new primary tumours
37,38
 and that irradiating a limited 
volume of breast would reduce treatment related morbidity. 
 
Randomised controlled trials of Partial Breast Irradiation versus Whole Breast Irradiation 
(level I evidence) 
 
Four randomised controlled trials (RCT) comparing WBI versus PBI have reported on their 
outcome. 
 
A group from The Christie hospital reported in 1993
39
. Their study randomised 708 patients 
with breast tumours ≤ 4 cm in diameter to PBI or WBI plus regional lymph nodes irradiation. 
PBI involved irradiating the tumour bed (with average field size 8 cm x 6 cm) to 40-42.5 Gy 
in 8 fractions over 10 days using electrons. WBI involved treating the whole breast to 40Gy 
in 15 fractions over 21 days using tangential fields with a matched field for regional lymph 
nodes. After a median follow up of 65 months, recurrence rates were higher in the PBI arm as 
compare to WBI arm (19.6% versus 11%; p=0.0008). The possible reasons for higher 
recurrence rates in the PBI arm were difficulty in defining the target volume, leading to 
geographical miss and the inclusion of patients with infiltrating lobular carcinoma and ductal 
carcinoma with an extensive intra-ductal component.  Patients with PBI were also found to 
have significantly higher rates of marked breast fibrosis (14% versus 5%) and telangiectasia 
(33% vs. 12%) compared to WBI.  
 
In another study, the Yorkshire Breast Cancer Group randomised 174 patients between WBI 
(with 40 Gy in 15 fractions over 21 days followed by a tumour bed boost of 15 Gy in 5 
fractions) and PBI, which used a variety of techniques, including direct cobalt or caesium 
beams, electrons or a small mega-voltage tangential pair to a dose of 55Gy in 20 fractions 
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over 28 days
40
. The trial closed prematurely due to poor accrual and higher loco-regional 
recurrence rates in the PBI group compared to the WBI group (24% versus 9%). It may be 
that the higher recurrence rate in the PBI arm was secondary to difficulty in accurate 
definition of the tumour bed. Treatment related morbidity with PBI and WBI has not been 
reported. These two studies pioneered the concept of PBI at a time when patient selection and 
tumour bed localisation were still very much under development. Subsequent randomised 
trials have more developed technology and used more stringent protocols for both of these 
factors. 
 
 The Hungarian National Institute of Oncology PBI trial
41
 and TARGIT trial
42
 have reported 
their outcomes more recently. The Hungarian PBI trial randomised 258 patients with stage T1 
N0-1 Grade ≤2 breast cancer to WBI or PBI following breast-conserving surgery41. WBI was 
carried out using Cobalt or photon beams to deliver a dose of 50 Gy in 2 Gy daily fractions, 
whilst and PBI was delivered using high dose rate (HDR) Iridium-192 brachytherapy (for 85 
patients) and a dose of 36.4 Gy in 5.2 Gy per fraction over 4 days or electrons (for 40 
patients) to a dose of 50 Gy in 2 Gy daily fractions prescribed to the 80% isodose level. At a 
median follow-up of 122 months, the local recurrence rates were not significantly different in 
the two arms of the trial. The cosmetic results using Harvard criteria
43
 were found to be 
favourable in the PBI arm. The rate for a cosmesis score of excellent to good was 81% for the 
PBI group and 63% for the WBI group (p =0.0015). 
 
The TARGIT-A trial randomised 2232 patients with early breast cancer to either i) WBI (40–
56 Gy) with or without a boost of 10–16 Gy or ii) intra-operative PBI using low energy x-
rays (50 kV and a dose of 20Gy to the tumour bed attenuating to 5–7Gy at 1 cm depth42). 
Patients with adverse histological features, which included invasive lobular carcinoma or an 
extensive intra-ductal component, also received WBI without a boost in the PBI arm. At two 
years, the local recurrence rate was similar with no significant difference in the rate of 
toxicity, but the type of toxicity was significantly different between the two trial arms. The 
WBI arm had higher RTOG grade 3-4 toxicity for dermatitis, telangiectasia or breast pain 
(2.1% versus 0.5%; p=0.002), whereas patients receiving intra-operative PBI experienced a 
different range of side effects. Breast seroma needing more than three aspirations was more 
common in the IORT PBI group (2.1% versus 0.8%; p=0.012) and more patients reported 
skin breakdown or delayed healing, required surgical evacuation of haematoma and 
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intravenous antibiotics or surgical intervention for infection.  Cosmetic results have yet to be 
reported. 
 
Case-matched pair studies (level III evidence) 
There have been four case match pair studies that have compared breast tissue complications 
for partial and whole breast irradiation.  
 
Polgar et al.
44
 selected 45 patients prospectively with stage T1N0-1 breast cancer who were 
treated with PBI using HDR Iridium-192 implants to a dose of 30.3-36.4 Gy delivered in 7 
fractions over 4 days and matched them to 80 patients (eligible for PBI) treated with WBI 50 
Gy in 2 Gy daily fractions with or without a tumour bed boost of 10 to 16 Gy. Analysis at a 
median follow up of 7 years, showed no significant difference in the ipsilateral breast 
recurrence rates in the two groups. Excellent or good cosmesis measured using Harvard 
criteria
43
 was seen in 84.4% patients in the PBI arm and 68.3% patients in the WBI arm 
(p=0.04). However, a trend of increased incidence of RTOG grade 2-3 fibrosis was seen in 
the PBI group compared to the WBI group without a boost dose (20% versus 5.8%; p=0.06).  
 
The William Beaumont group matched 174 patients treated with PBI (with low dose rate I125 
implants delivering 50 Gy over 96 hours at a dose rate of 0.52 Gy/hour or HDR implants 
delivering 32 Gy in 8 fractions, each separated by 6 hours),  with 174 patients treated with 
WBI with a median total tumour bed dose of 60 Gy
45
.  At a follow up of 36 months, cosmetic 
outcome was more favourable in the PBI group than the WBI group (excellent or good 
cosmesis was seen in 90% versus 83% of patients) This was not found to be statistically 
significant (p=0.17). 
 
King et. al.
46
 matched 51 patients treated with PBI delivered with low dose rate Ir192 
implants to achieve 45 Gy over 4 days (or HDR implants of 32 Gy in 8 fractions over 4 days) 
to 94 patients treated with WBI to a mean dose of 59 Gy following breast-conserving surgery. 
A blinded panel of experts scored photographic assessment of cosmesis on a four-part scale 
(excellent, good, fair, poor). At 20 months follow up, 75% patients in the PBI group and 84% 
patients with WBI had excellent or good cosmesis (not statistically significant). Grade I and 
II treatment complications including skin erythema, desquamation, discoloration, 
hyperpigmentation, dimpling; breast pain, tenderness, shrinkage or fibrosis were significantly 
more common in the WBI arm than the PBI study arm (80% versus 22%, p=0.001). Grade III 
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treatment complications requiring surgical intervention were not found to be different in the 
two groups (8% versus 5%, p=not significant). 
 
Tata Memorial Hospital, India matched 27 patients treated with PBI using HDR 
brachytherapy (34 Gy in 10 fractions over 6-8 days) with 67 patients treated with WBI (45 
Gy in 25 fractions over 5 weeks followed by a tumour bed boost using electrons (15 Gy in 6 
fractions or interstitial HDR brachytherapy with a single 10 Gy fraction)
47
. They reported that 
at a median follow-up of 43 months, cosmetic outcome was superior in the PBI group 
compared to the WBI group (excellent or good cosmesis was 88.9% versus 56%; p=0.003). 
No significant difference was seen in the rates of moderate or severe breast fibrosis. 
 
Effect of treatment volume on NTCP in PBI series 
There are several publications reporting on the efficacy and low toxicity achievable with PBI, 
but only a few evaluate the impact of treatment volume on NTCP. The current literature on 
the volume effect of PBI for 3D-CRT/IMRT, electrons and brachytherapy is summarised 
below. 
 
 3D-CRT/IMRT based PBI (level IV evidence) 
Jagsi et. al.
48
 presented the cosmetic outcome of 32 patients treated with PBI using IMRT at 
deep inspiration breath hold. The patients received 38.5 Gy twice daily over five consecutive 
days. At a median follow up of 2.5 years, 22% patients were scored as having unacceptable 
cosmesis. Retrospective comparison between patients with acceptable and unacceptable 
cosmesis showed that the mean percentage volume of the breast receiving a minimum of 
100% of the prescribed dose i.e. 38.5 Gy (V100) was lower in patients with acceptable 
cosmesis as compared to patients with unacceptable cosmesis (15.5% versus 23.0%; p=0.02). 
The mean percentage volume of breast receiving a minimum of 50% of the prescribed dose 
i.e. 19.25 Gy was also smaller in the group with acceptable cosmesis compared to 
unacceptable cosmesis group (p=0.02).  
 
Hepel et. al.
49
 also reported on a positive correlation between the volume of breast tissue 
treated with PBI and cosmesis outcome. 60 patients were treated with PBI to a dose of 38.5 
Gy in twice daily fractionations over one week using 3D-CRT. At a median follow up of 15 
months, 18% patients developed fair or poor cosmesis and 25% developed Grade 2-4 
subcutaneous fibrosis. In univariate analysis, the ratio of the size of 3D-CRT target volume to 
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the whole breast volume was found to correlate with fair or poor cosmesis (p=0.02) and with 
grade 2-4 subcutaneous fibrosis (p=0.10). Reference 48 and 49 suggested an association 
between breast volume irradiated in PBI and normal tissue complication rates. 
 
In contrast, Chen and colleagues from the William Beaumont group reported no association 
between overall cosmesis and the ratio of the size of 3D-CRT target volume to the whole 
breast volume
50,51
. In their study 94 patients received PBI with a dose of 38.5 Gy in twice 
daily fractions over five consecutive days using 3D-CRT. Of the 56 patients with cosmesis 
assessment of greater than 48 months, 11% had fair to poor cosmesis and 3% had Grade 3 
fibrosis with no association between cosmesis or subcutaneous toxicity and this ratio. 
 
Single source brachytherapy and multi-source brachytherapy (level IV evidence) 
Multi-source brachytherapy has been used for PBI for many years. Most publications on the 
results of this technique focus on local control rates and there is limited reporting of normal 
tissue toxicity. Some have reported on factors associated with normal tissue toxicity and have 
commented on a positive correlation between NTCP and the implant volume. Yeo et. al.
52
 
reported on the efficacy and safety of PBI using multi-source brachytherapy for 48 patients 
with a median follow up of 53 months. A dose of 34Gy in 10 fractions over five days was 
delivered to the tumour bed plus a margin of 1 to 2 cm. 14% of patients developed Grade 2 
subcutaneous toxicity with V100 and V150 significantly higher in these patients (p=0.018 
and 0.034 respectively). No patients were found to have poor cosmesis. 
 
Wazer et al.
53
 studied late toxicity and long term cosmetic outcome after multi-source 
brachytherapy PBI using pooled data from Tufts University, Brown University and Virginia 
Commonwealth University. The number of dwell positions, a determinant of total volume of 
implanted breast tissue, was found to correlate with late cosmetic outcome (p=0.04). 
 
Lawenda and colleagues found no association between implant volume and overall cosmetic 
outcome for 48 patients treated with LDR brachytherapy at their centre from 1997-2001
54
. 
The purpose of the study was to evaluate the effects of dose escalation in PBI. The dose was 
escalated in three groups of 50 Gy, 55 Gy and 60 Gy and implant volume was divided into 
four groups. A trend between dose escalation and fibrosis was seen (not found to be 
significant). They also observed a decline in the incidence of breast fibrosis with increase in 
implant volume, a finding contrary to other published literature. 
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Trial/Institute Control arm (WBI) Test arms (PBI): treatment 
modality 
Median 
follow up 
(months) 
Target accrual Reported 
Christie group trial
39
 WBI 40Gy in 15 fractions with 
matched field for regional nodes 
PBI: 40-42.5Gy in 8 fractions 
using electrons 
65 months 708 Yes 
Yorkshire Breast Cancer 
Group trial
40
  
WBI 40Gy in 15 fractions with 
15Gy boost 
PBI using direct cobalt, caesium 
or electrons beam or a small 
mega-voltage tangential pair to a 
dose of 55Gy in 20 fractions 
96 months 174 
(pre-mature 
closure) 
Yes 
Hungarian National 
Institute of Oncology
41
  
WBI using Cobalt or photons 
beam to a dose of 50Gy in 25 
fractions over 5 weeks 
HDR Ir-192 (85 pts) to a dose of 
36.4Gy in 7 fractions over 4 
days or Electrons (40 pts) to a 
dose of 50Gy in 25 fractions 
prescribed to the 80% isodose 
66 258 Yes 
TARGIT
42
 WBI 40–56Gy with optional boost 
of 10–16Gy 
PBI: 20Gy single fraction using 
Intra-operative 50 KV photons 
24 months 2232 Yes 
ELIOT
55
 WBI 50Gy in 25 fractions with 
10Gy boost 
PBI: Intra-operative electrons 
21Gy in single fraction 
NA 1300 
(closed 2007) 
No 
IMPORT LOW
56,57
 WBI 40Gy in 15 fractions, no 
boost 
Arm 1: 36Gy in 15 fractions to 
the low risk volume of the breast 
and 40Gy in 15 fractions to the 
NA 2000 
(closed 2010) 
No 
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index quadrant  
Arm2 (PBI): 40Gy in 15 
fractions over 3 weeks to the 
index quadrant only 
GEC-ESTRO
58 
WBI 50-50.4Gy in 25-28 fractions 
with 10Gy optional boost 
PBI: 32 Gy in 8 fractions or 
30.3Gy in 7 fractions HDR or  
50Gy PDR 
NA 1170 
(activated  2004) 
No 
NSABP-39
59
 WBI 50-50.4Gy in 25-28 fractions 
with 10-16Gy optional boost  
PBI: 34Gy in 10 fractions over 
five days using single/multi-
source brachytherapy or 38.5Gy 
in 10 fractions over 5 days using 
3D-CRT 
NA 4300 
(activated 2005) 
No 
RAPID
60
 WBI 42.5Gy in 16 fractions with 
optional 10Gy boost 
PBI: 38.5Gy in 10 fractions BD 
over 5-8 days using 3D-CRT 
NA 2128 
(activated  2006) 
No 
IRMA
61
 WBI 45Gy in 18 fractions or 50Gy 
in 25 fractions or 50.4Gy in 28 
fractions with optional 10 – 16Gy 
boost 
PBI: 38.5Gy in 10 fractions BD 
over 5 days using 3D-CRT 
NA 3302 
(activated 2007) 
No 
Danish Breast Cancer Co-
operative Group
62
 
 
WBI 40Gy in 15 fraction  PBI: 40Gy in 15 fraction using 
3D-CRT 
NA 628 
(activated 2009) 
No 
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SHARE
63 
WBI 50Gy in 25 fractions + 16 Gy 
boost or WBI 40-42.5Gy in 15-16 
fractions without boost 
 
PBI: 40Gy in 10 fractions BD 
over 5 to 7 days using 3D-CRT 
NA 2796 
(activated 2010) 
No 
 
 
Table 2: Phase II-III randomised controlled trials comparing WBI versus PBI
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Breast fractionation studies 
 
The Royal Marsden Hospital and Gloucestershire Oncology Centre (RMH/GOC) 
trial
16
 randomised 1410 early breast cancer patients between three fractionation 
schedules for WBI. The control arm treatment was 50Gy in 25 fractions delivered in 5 
weeks. Two test arms were used: a) 39Gy in 13 fractions over 5 weeks, and b) 42.9Gy 
in 13 fractions over 5 weeks. The equivalent doses in 2 Gy fractions (EQD2) (using 
an α/β ratio of 3.1 Gy for palpable breast induration) were calculated to be: 46.7 Gy 
and 53.8 Gy respectively. The risk of moderate to severe induration at 10 years for the 
two test arms was 27% and 51%, respectively, suggesting a 24% increased risk of 
induration with a dose escalation of 7 Gy to the whole breast (or 3.3 % increased risk 
per Gy). Compared to this fractionation effect, an escalated dose to the tumour bed 
alone i.e. a boost of 15.5 Gy delivered in 7 fractions (EQD2 of 16 Gy) increased the 
risk of induration by 17% (equivalent to a 1.05% increase per Gy). The increased risk 
of induration, per Gy of dose seen with increased breast volume irradiated indicates a 
radiation volume-effect for breast tissue. 
 
Dose modulating effect on the breast 
 
The dose volume effect in normal-tissue can be exploited therapeutically by radiating 
a small volume of tissue to a higher dose and reducing the overall dose to the rest of 
the organ. This has been successfully demonstrated in prostate cancer radiotherapy 
with IMRT
64
.  A trial at Saint George and Wollongong in Sydney suggests that this 
modulation effect is also present in breast tissue
65
. This trial randomised 688 patients 
with stages T1-2N0-1 breast cancer between a standard arm of WBI (50 Gy in 2 Gy 
daily fractions and no boost) and test arm of WBI (45 Gy in 1.8 Gy daily fractions 
plus a 16 Gy tumour bed boost). The overall cosmesis was scored by a five-person 
panel using digital photographs with a scale of excellent, good, fair and poor. 79% 
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patients in the test arm with boost and 68% patients in the standard arm had excellent 
or good cosmesis (p=0.016). The rate of moderate to severe breast fibrosis at five 
years was similar in the treatment arms. These results are contrary to the current 
literature of worse cosmetic outcome and higher rates of breast fibrosis with 
additional boost radiation. A possible explanation for these results is that a modest 
reduction in dose to the whole breast allowed dose escalation to the tumour bed 
without the expected increase in normal tissue toxicity and provides evidence of a 
volume effect. 
 
Limitations of this review 
 
Late breast tissue toxicity post radiotherapy is influenced by several patient and 
treatment related factors. Many of the studies reviewed have not accounted for other 
confounding factors including extent of surgical excision, total delivered dose, dose 
fractionation, post-operative complications and brachytherapy dose inhomogeneity, 
e.g. surgical excision volume and baseline surgical cosmesis are significant factors 
affecting cosmesis
15,66-68
. Larger surgical excision would also imply larger 
brachytherapy boost and/or target volume and a larger applicator size for IORT. 
Based on the current reports, it is difficult to draw strong support on the independent 
volume effect on late breast tissue complications. 
 
A variety of treatment approaches have been used including photons, electrons, intra-
operative techniques and brachytherapy. In addition, the reported studies have used 
different endpoints (fibrosis, cosmesis and telangiectasia) with several different 
scoring methods and a range of periods at which follow-up were obtained. These 
factors all make it difficult to draw firm conclusions on the dose-volume relationship 
for breast tissue.  
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Conclusions 
 
Quantitative effect of treatment volume 
The study by Borger et al.
14
 which used low dose rate iridium implants provided the 
most robust quantitative data on the dose-volume relationship. For every 100 cm
3
 
increase in the boost volume, the risk of fibrosis increased by a factor of four and a 
two-fold increase in boost volume results in an 11% reduction in tolerance dose 
(NTD50). It is however difficult to be certain as to how the low dose rate 
brachytherapy data can be extrapolated to other techniques: HDR brachytherapy, 
electron and photon boost techniques. The RMH/GOC trial
16
 which used electron 
boost provides indirect quantitative information on the dose volume relationship for 
NTCP. For every Gy increase in boost dose, the risk of moderate to severe breast 
induration was found to increase by 1% as compared to 3% when the whole breast 
dose is increased by 1 Gy. 
 
Qualitative effect of treatment volume 
The results from the Hungarian PBI trial
41
 and TARGIT trial
42
 provides strong 
qualitative evidence of a dependence of NTCP on volume irradiated. These studies 
report both improved cosmetic outcome and reduced NTCP in the PBI arm compared 
to WBI. However, these are significant differences in the radiotherapy techniques and 
fractionation schedules used by these two groups, making it difficult to draw 
quantitative conclusions on the radiation volume effect on breast tissue. The other 
reported randomised trial from Christie reported higher rates of breast fibrosis and 
telangiectasia in the PBI arm
39
. A dose-response relationship for late radiation effects 
including telangiectasia and breast fibrosis is well known
2,69,70
 and these dissimilar 
results may be explainable if one calculates the 2Gy equivalent dose (EQD2) for the 
PBI and WBI groups using an α/β ratio of 3.116 for fibrosis. The WBI group received 
 50 
 
a lower dose of 45 Gy (EQD2), compared to 63-70 Gy for the PBI group in the 
Christie study.  
 
The four matched case series
44-47
 which compared PBI and WBI also showed 
favourable cosmesis and lower NTCP risk with PBI with the exception of higher 
grade 2-3 fibrosis observed in the Hungarian series
44
. It is possible that significant 
dose heterogeneity with the use of Ir192 implants could explain the increased grade 2-
3 fibrosis in the PBI arm in the Hungarian series. As in the randomised trials, this 
study evaluated PBI and WBI using different radiotherapy techniques and 
fractionation. 
 
Future work 
 
The current literature suggests that treatment volume is an important parameter 
affecting late breast tissue complications but that more robust data is needed. This is 
expected to come from the below mentioned randomised trials which will quantify the 
impact of volume of breast irradiated on NTCP. 
 
 Randomised controlled trials of Partial Breast versus Whole Breast Irradiation 
IMPORT LOW and The Danish Breast Cancer Cooperative Group trial (which has 
not yet reported) are two randomised trials comparing PBI and WBI, with volume of 
breast irradiated as the solitary randomisation variable. IMPORT LOW is a 
randomised Phase 3 trial comparing WBI with two dose levels delivered as PBI using 
IMRT in women with low risk of recurrence from their breast cancer. It has 
completed target accrual of 2000 patients in 2010
56-57
. The control arm is WBI 
delivering 40 Gy in 15 fractions over 3 weeks to the whole breast. Test arm 1 delivers 
synchronously 40 Gy in 15 fractions to the partial breast PTV and 36Gy in 15 
fractions to the remainder of the whole breast. Arm 2 uses PBI to deliver 40 Gy in 15 
 51 
 
fractions to the partial breast PTV alone (see figure 1). The primary endpoint is local 
tumour control in the treated breast. Secondary endpoints include location of tumour 
relapse, occurrence contralateral primary tumours, regional and distant metastases, 
late adverse effects in normal tissues, quality of life (QOL) and economic evaluation.  
 
The trial implemented by the Danish Breast Cancer Cooperative Group is a Phase 2 
study comparing PBI to WBI in low risk breast cancer patients. Both treatment arms 
receive 40Gy in 15 fractions over 3 weeks
62
. The primary endpoint for this study is 
grade 2-3 breast fibrosis after radiotherapy. Secondary endpoints are other late 
morbidity, local recurrence and genetic risk profiling for development of late radiation 
morbidity. The results on these two trials in terms of late normal tissue effects will not 
become available for several years, but are expected to provide definitive data 
regarding the effects of irradiated breast volume on normal tissue effects.  
  
 52 
 
 
 
 
 
 
 
 
 
Figure 1: IMPORT LOW trial schema 
 
3D-CRT/IMRT based PBI trial 
The 3D-CRT/IMRT based PBI series
48-50
 discussed above have produced conflicting 
reports on the relationship between the treated volume and NTCP. The mature data 
from the on-going Phase 3 NSABP B-39/RTOG 0413 trial (n=4300) is expected to 
provide more definitive data on whether an association between breast volume 
irradiated in APBI and normal tissue complications exists.  
 
 
 
 
CONTROL 
40Gy/15Fr 
TEST ARM1 
1 
40Gy/15Fr 
36Gy/15Fr 
TEST ARM 2 
40Gy/15Fr 
Control: Whole breast irradiation, 40Gy in 15 fractions over 3 weeks  
Arm1: 36Gy in 15 fractions to the low risk volume of the breast and 40Gy in 15 
fractions to the index quadrant over 3 weeks 
Arm 2: Partial breast irradiation, 40Gy in 15 fractions over 3 weeks to the index 
quadrant only 
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Dose modulation effect on the breast 
This dose modulating effect on the breast tissue is further investigated in the IMPORT 
HIGH trial (of which this study is sub-study)
56,57
. The trial randomises patient at 
higher risk of recurrence between three groups: a) a standard arm of 40 Gy in 15 
fractions to the whole breast over 3 weeks with a sequential tumour bed boost of 16 
Gy in 2 Gy daily fractions; b) test arm 1 of 36 Gy in 15 fraction to the low risk 
volume of the breast, 40 Gy in 15 fractions to the index quadrant plus a concomitant 
tumour bed boost of 48 Gy in 15 fractions; and c) Test arm 2 of 36Gy in 15 fractions 
to the low risk volume of the breast, 40 Gy in 15 fractions to the index quadrant plus a 
concomitant tumour bed boost of 53 Gy in 15 fractions. The trial planning schema is 
shown in figure 2. This trial tests the hypothesis that decreasing the radiation the dose 
to the whole breast volume by a very small amount (40 Gy to 36 Gy) and treating an 
iso-effective dose to the index quadrant and tumour bed (Test arm 1), may result in 
less normal tissue side effects compared to the control group. It will also test if 
decreasing the radiation dose to the whole breast tissue by a very small amount allows 
dose escalation to the tumour bed (which area of highest risk of local recurrence) 
without an increase in normal tissue side effects (Test arm 2). 
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Figure 2: IMPORT HIGH trial schema
CONTROL 
40Gy/15Fr 
TEST ARM 1 
40Gy/15Fr 
36Gy/15Fr 
TEST ARM 2 
40Gy/15Fr 
36Gy/15Fr 
56 Gy/23 Fr 
sequential 
dose 
escalation 
48 Gy/15 Fr 
concomitant 
dose 
escalation 
53 Gy/15 Fr 
concomitant 
dose escalation 
Control: 40Gy in 15 fractions to the whole breast followed by a sequential photon 
boost of 16Gy in 8 fractions to the tumour bed (Total- 56Gy in 23 fractions 
sequential dose) 
 
Test Arm 1 and 2: 36Gy in 15 fractions to the low risk volume of the breast, 
40Gy in 15 fractions to the index quadrant and dose escalation to the tumour bed 
with two dose levels of 48Gy and 53Gy in 15 fractions as concomitant boost 
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Chapter 3 – Normal tissue complication modelling for breast tissue 
 
This chapter describes the development of a normal tissue complication probability 
(NTCP) model which may be used to relate the volume of normal tissue irradiated to 
the risk of toxicity. This model is required to address a secondary objective of this 
study: to estimate the reduced risk of late adverse effects resulting from the smaller 
tissue volume irradiated.  
 
This chapter is based on the peer reviewed scientific refereed journal paper: 
Mukesh MB, Harris E, Collette S, Coles CE, Bartelink H, Evans PM, Graham P, 
Haviland J, Poortmans P, Yarnold J, Jena R. Radiother Oncol 2013: 108:293-298. 
 
Introduction 
 
The goal of this stage of the work was to develop an NTCP model for breast tissue 
and predict the probability of complication to quantify the dose-volume effect for a 
non-uniform irradiation of the patient‟s breast. Fibrosis is a common sequela of breast 
RT and adversely affects overall cosmesis, it can be assessed using a scoring system 
and has been shown to impact on patient physical and psychological wellbeing
12
. 
Hence, this work relates to the development of NTCP model for moderate-severe 
breast fibrosis. 
 
The hypothesis in this work was that breast tissue displays a significant dose-volume 
effect to radiation which manifests itself as moderate to severe fibrosis and that an 
NTCP model can effectively predict the probability of breast fibrosis based on the 
interaction of radiation dose and the treatment volume. 
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Materials and methods 
 
This analysis required diverse datasets with a range of dose and volume data plus 
quantitative toxicity endpoint data. Randomised clinical trials (RCTs) were felt to 
provide the most robust data to this end. In addition pooling data from a set of RCTs 
was felt to increase the diversity of the dataset and enable generalisation of the 
findings to a broader population
71
. Moderate to severe breast fibrosis was chosen as 
the toxicity endpoint for this study. 
 
The principal investigators of three trials kindly agreed to collaborate by sharing their 
patient data. 
i) Dr. Charlotte Coles from the Cambridge Breast IMRT trial
66,72
 
ii) Professor Harry Bartelink from the EORTC 22881-10882 “boost versus no 
boost” trial2,25 
iii) Dr. Peter Graham from the St. George and Wollongong trial
65
 
 
Preliminary assessment of the available data, showed that the moderate-severe breast 
fibrosis rate of 3% with 50 Gy WBI in the St George and Wollongong trial was 
smaller than that in the published literature (including the Cambridge and EORTC 
trials). Hence, for this study, only individual patient data from the EORTC 22881-
10882 “boost versus no boost” trial and the Cambridge Breast IMRT trials were 
pooled. 
 
Patient cohort details and toxicity scoring – Cambridge 
This was a single centre trial which recruited 1145 patients with invasive breast 
cancer (stage T1-T3N0-1M0) or ductal carcinoma in situ who received breast 
conserving surgery and radiotherapy.  All patients received 40 Gy in 15 fractions over 
3 weeks to the whole breast, which was followed by an electron tumour bed boost of 9 
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Gy in 3 fractions over 3 days in selected cases (n = 728). The level of breast fibrosis 
was assessed clinically at 2 and 5 years after completion of RT and scored on a four 
point scale (0 = none, 1 = a little, 2 = moderate and 3 = severe). 
 
Patient cohort details and toxicity scoring – EORTC 
This was a multi-centre trial that recruited 5569 patients with invasive breast cancer 
(stage T1-T2N0-1M0) who received surgery and radiotherapy. All patients received 
50 Gy in 25 fractions over 5 weeks to the whole breast and were randomised by three 
boost levels: i) no boost (n = 2657), ii) 10 Gy in 5 fractions boost (n = 126), iii) 16 Gy 
in 8 fractions boost (n = 2661), and iv) 26 Gy in 13 fractions boost (n = 125). The 
boost was delivered using: electrons (63%), photons (29%) and low dose rate 
brachytherapy (9%). Breast fibrosis was assessed clinically at each follow up visit and 
scored on a four point scale (1= none, 2 = minor, 3 = moderate, and 4 = severe). 
 
Exclusion criteria 
As brachytherapy may lead to significant dose heterogeneity and the boost volumes 
used are usually much smaller than external beam techniques
73
 patients with 
brachytherapy boost were excluded from the analysis as were patients with missing 
data or toxicity scores (Cambridge trial: 571 and EORTC trial: 275). 
 
 Dose-Volume data 
The accuracy with which NTCP model parameters can be estimated depends on the 
quality of dosimetry and follow-up data. The late toxicity scores and boost volumes 
were recorded in both trials but limited data on the dose distributions were available. 
Consequently, a more simplistic two-compartment dose-volume histogram (DVH) 
model was used. The first step of the DVH was the tumour bed volume receiving the 
whole breast dose plus the boost dose and the second step of the DVH was the 
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remaining breast volume (whole breast volume minus tumour bed volume) receiving 
whole breast dose only (figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: The two step dose volume histogram model 
 
DVH step 1: Tumour bed receiving the whole breast dose plus the tumour bed boost 
DVH step 2: Whole breast volume minus the tumour bed receiving whole breast dose 
alone 
 
The whole breast volume was only recorded in the Cambridge trial. Based on the 
Cambridge data, estimates of the whole breast volume for the EORTC trial patients 
could be estimated. Hence, a Monte Carlo (MC) simulation method was written which 
generated breast volume data for these patients. The MC simulation used the breast 
volume distribution from the Cambridge trial and an acceptance-rejection test for the 
randomly generated volumes to ensure the ratio of boost/breast volume was between 
5-40% (the range of boost volume to breast volume ratio observed in the Cambridge 
data). In doing this the assumption was made that the distribution of breast volume 
 
 
 Tumour 
bed 
Whole breast 
minus tumour bed 
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and the ratio boost/breast volume in the EORTC trial was the same as that in the 
Cambridge trial. 
 
NTCP modelling  
In this study two established radiobiological models were used: Lyman Kutcher 
Burman (LKB) model
74
 and the Niemierko model
75
. Both assume that the dose-
response follows a sigmoid curve. Both describe the response with three parameters: 
TD50: the homogeneous dose to the organ that leads to 50% patients experiencing the 
defined toxicity at 5 years 
γ50/m: the steepness parameter of the dose-response curve  
n:  volume parameter of the organ being assessed 
 
To estimate these parameters, each patient‟s two-compartment DVH was converted 
into a generalised equivalent uniform dose (EUD) using the Kutcher-Burman 
histogram reduction method. The EUD is the dose, when delivered uniformly to the 
organ, will lead to the same complication probability as the actual dose distribution.  
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vi is the i-th sub-volume of the organ irradiated with dose Di in the differential dose-
volume histogram. 
  
For the volume parameter, n, If n=1, the organ has a parallel structure with a strong 
volume dependence on late complication rate and EUD is the mean dose, If n=0, the 
organ has a serial structure with no volume dependence on late complication rate and 
EUD tends to be the maximum dose. 
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As complications due to radiotherapy depend on fraction size, a biologically 
equivalent uniform dose (BEUD3) was generated using the EUD and α/β ratio of 3Gy 
in the linear quadratic model.  
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In the Lyman Kutcher Burman (LKB) model: 
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In the Niemierko model: 
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The two NTCP models were written in Object Pascal (Delphi, Embarcadero 
technologies, San Francisco, CA, USA). 
 
A Maximum Likelihood Estimation (MLE) method
76
  was used to find the best-fit 
values of the model parameters BEUD50, γ50/m and n. This method estimates the 
probability that the observed pattern of complications can be best described by the 
parameters of the model. 
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where y(i)=1 if moderate or severe fibrosis is observed and y(i)=0 if moderate or 
severe fibrosis is absent. 
 
As discussed above, value of n value close to 1 suggest that the organ has a parallel 
structure with a strong volume dependence whilst a value of n close to zero suggests 
that the organ has a serial structure with little or no volume dependence on late 
complication rate. A full sequential parameter search was carried out using the 
following parameter constrains: BEUD3 (0-150), n (0.01-1.0), γ50 (0.5-3.0) and m 
(0.1-0.8). The 95% confidence intervals (CI) for the optimally fit parameters were 
obtained using the Profile Likelihood Estimation method
77
. The parameter of interest 
was varied around its optimal values, while the other parameters were fixed in the 
MLE to generate the upper and lower 95% CI. This method takes non-linearity and an 
asymmetrical CI into consideration but does not account for correlations between 
parameters. 
 
Results from the START-pilot trial
16 
were used to assess the goodness of fit of the 
predicted NTCP models. The START-pilot trial randomised 1410 patients into three 
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whole breast RT dose fractionations: i) 50 Gy in 25 fractions, ii) 39 Gy in 13 
fractions, and iii) 42.9Gy in 13 fractions. Patients were also sub-randomised for 
tumour bed boost to a dose of 14 Gy in 7 fractions using electrons. Cumulative data 
on moderate or severe breast induration at 5 years were used for all three whole breast 
dose fractionation regimes with and without the boost to test the goodness of fit. The 
goodness-of-fit statistic was obtained by calculating the Pearson chi-square statistic 
for the observed and predicted rates of breast fibrosis. The statistic is denoted as χ2 
and a large values of χ2 (and small p-values) indicate a lack of fit of the model.  
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„O‟ is the observed rates of fibrosis and „E‟ is the rate of fibrosis predicted by the 
model. 
 
Results 
 
Dose-volume and toxicity data for 574 patients from the Cambridge trial and 5282 
patients from the EORTC trial were used for the NTCP modelling. 26.8% (154/574) 
patients in the Cambridge trial and 20.7% (1096/5282) patients in the EORTC trial 
developed moderate or severe breast fibrosis. The patient‟s radiotherapy dose volume 
characteristics are summarised in table 3 below. 
 
 
 
 
 
 
 63 
 
 
 Number of 
patients 
Mean boost 
volume (range) 
Moderate-severe fibrosis 
rates 
Cambridge dataset (assessed at 5-year) 
No Boost 235 - 40/235 (17%) 
Boost 339 161.2 (33.6-540cc) 114/339 (33.6%) 
EORTC dataset (cumulative incidence at 10 years)* 
No boost 2656 - 341/2656 (12.8%) 
≥6Gy to <10Gy 6 238 (108-372cc) 1/6 (16.7%) 
10Gy 117 204.7 (42-1176cc) 28/117 (23.9%) 
12Gy 31 185.9 (48-606cc) 11/31 (35.5%) 
14Gy 93 273.4 (48-735cc) 23/93 (24.7%) 
16Gy 2257 209 (22-1386cc) 635/2257 (28.1%) 
>16Gy to ≤20Gy 39 193.1 (52-630cc) 9/39 (23.1%) 
26Gy 83 198.5 (43-630cc) 48/83 (57.8%) 
* The NTCP parameter estimation was based on the actual tumour bed boost dose 
delivered and not on the intention to treat boost dose 
 
Table 3: Dose-volume characteristics from the Cambridge and the EORTC dataset 
used for the NTCP model 
 
The best estimated NTCP parameters for the Niemierko model from the MLE method 
were BEUD3(50) = 136.4 Gy, γ50=0.9 and n=0.011. The 95% CI for parameters were 
BEUD3(50) = 132.8-140 Gy, γ50= 0.84-0.97 and n= 0.01-0.03. The best estimated 
parameters for the LKB model were BEUD3(50) = 132 Gy, m= 0.35 and n= 0.012 
with 95% CI of BEUD3(50) = 128.8-135.6 Gy, m= 0.326-0.374 and n= 0.01-0.03. The 
results of both models strongly imply that the risk of moderate-severe breast fibrosis 
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is strongly associated with radiotherapy dose and the effect of volume (i.e. the volume 
parameter) is small. The BEUD3(50) values of 136.4 Gy and 132 Gy correspond to 
EQD2 values (equivalent doses in 2 Gy fractions) of 79.2 Gy and 81.8 Gy 
respectively. 
 
The observed rates of moderate-severe fibrosis in the RMH/GOC trial were in good 
agreement to the predicted rates of fibrosis using the LKB model (see figure 4) and 
the Niemierko model (see figure 5). Using the Pearson chi-square test with 5 degree 
of freedom, the χ2 was 0.053 (p=0.95) for the LKB model and χ2 was 0.058 (p=0.95) 
for the Niemierko model suggesting a good fit for both models. 
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Figure 4: Lyman Kutcher Burman Model - The probability of moderate-severe breast 
fibrosis versus biological equivalent dose using α/β of 3 Gy (BED3). The solid line is 
based on the best-fit parameters (BED3 = 132 Gy and m= 0.35) and the dashed lines 
are upper and lower 95%CI. The summative toxicity data of the three dose 
fractionations ± boost at five years from the START pilot trial are plotted. 
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Figure 5: Niemierko Model - The probability of moderate-severe breast fibrosis 
versus biological equivalent dose using α/β of 3 Gy (BED3). The solid line is based on 
the best-fit parameters (BED3 = 136.4 Gy and γ50 = 0.9) and the dashed lines are 
upper and lower 95%CI. The summative toxicity data of the three dose fractionations 
± boost at five years from the START pilot trial are plotted. 
 
Three previous studies have estimated the NTCP parameters for breast fibrosis and 
these results are summarised in table 4. The Borger et al.
14
 model was based on 404 
patients treated with WBI (50 Gy in 25 fractions over 5 weeks) followed by low dose 
rate Ir192 tumour bed boost (15-25 Gy). BEUD was calculated using α/β of 2 Gy and 
repair half-time of 1.5 hours. The positions of the implants were reconstructed on 
radiographs and dose distributions calculated. The best-fit model parameters in the 
study were found to be TD50= 72 Gy and n= 0.16 ± 0.04. The model parameters were 
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estimated from patients with brachytherapy boost alone and it is not clear how to 
compare parameters generated from brachytherapy to external beam techniques due to 
inherent differences in the dose distributions and possibly different radiobiological 
effects. Hence patients with brachytherapy boost were excluded in the current study. 
Avanzo et al.
78
 estimated the best fit parameters for the model using average values of 
dosimetric parameters (prescription dose, fraction dose, median follow up and dose-
volume data) from three WBI studies without boost and four external beam PBI 
studies. Three of the PBI studies used twice daily fractionation, and BEUD 
calculations included a repair half-time of 4.4 hours in the model. As the median 
follow up of the PBI studies was short (1.3-4.2 years), a latency function correction 
was also included. The parameters were estimated using the weighted least square 
fitting method, with the number of patients in each dataset used as weighting. The 
parameters found for moderate and severe breast fibrosis from the model were 
BEUD50= 105.8, n=0.15 and m=0.22.  
 
Alexander et al.
79
 reported that the volume parameter exhibited a strong effect on 
breast fibrosis. This study included summative data of 806 patients from the START 
pilot trial
16
, 590 patients from a German study
80
 and 150 post-mastectomy patients 
treated in the 1960‟s81. All patients received WBI and no partial volume data was 
available for the fitting analysis. The dose-volume data were generated using an 
anthropomorphic phantom and parameters were estimated for a relative seriality 
model and Lyman model. The study suggested a parallel structure for breast tissue 
with a strong volume effect for breast fibrosis (n=0.78). However, these results cannot 
be generalised for several reasons: 
i. The study did not account for the tumour bed boost doses (additional RT dose) 
in the models. 
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ii. Different toxicity outcome measures are used in the studies. The START pilot 
and German study assessed breast fibrosis based on clinical examination, 
whereas the post-mastectomy study used photographic assessment. 
iii. The planning techniques for the post-mastectomy study based on 1960s data are 
outmoded by present standards. Different NTCP parameters may be expected 
for breast fibrosis after BCS and tissue fibrosis after mastectomy. 
iv. The study corrected for latency time (START pilot and German) based on the 
results of the historic post-mastectomy series. 
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* these studies used summative dosimetric and toxicity data 
 
NTD: Normalised total dose 
BEUD3(50): Biologically equivalent uniform dose using α/β of 3Gy 
γ50/m: slope of the dose response curve 
n: volume parameter  
t1/2: repair half-time 
s: describes the serial/parallel architecture of the organ. A large value indicates a 
serial structure and a small value indicates a parallel structure 
 
 Number of 
patients 
BEUD3(50) γ50 m n 
Borger et al.
14
  
404 
NTD50=72 Gy 
(α/β =2Gy) 
(t1/2 = 1.5hrs) 
  0.16 
Alexander et al*
79
 
 LKB model 
 Relative seriality 
model 
 
1546  
 
104 Gy 
104 Gy 
 
- 
1.47 
 
0.27 
 
0.78 
(s=0.12) 
 
Avanzo et al*
78
 
 with repair 
correction ((t1/2  = 
4.4hrs) 
 without repair 
correction 
 
2562 
 
105.8 Gy 
107.2 Gy 
 
- 
 
0.22 
0.22 
 
0.15 
0.06 
Current study  
 LKB model 
 Niemierko model 
 
5856 
 
132 Gy 
136.4 Gy 
 
 
0.9 
 
0.35 
 
0.012 
0.011 
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Table 4: Summarised results of the best fit NTCP parameters for moderate-severe 
breast fibrosis 
 
Discussion 
 
A better understanding of the dose-volume effect for breast tissue is timely as many 
patients now receive non-uniform breast irradiation in form of a variety of modern 
techniques: accelerated PBI, simultaneous integrated boost and risk adapted 
radiotherapy
56,59,82,83
. The EORTC 22881-10882 trial breast fibrosis nomogram 
showed a strong association between radiotherapy dose and risk of fibrosis, with large 
boost volumes as a prognostic factor based on univariate analysis only
26
. The purpose 
of this study was specifically to investigate the volume effect by developing a NTCP 
model based on the data. This was approached by pooling individual data from two 
large prospective trials (5856 patients) that offered robust information on radiotherapy 
dose, boost volume and late toxicity. 
 
Using the MLE method, the volume parameter „n‟ was close to zero for both the LKB 
model and the Niemierko model analyses. This finding suggests that for moderate and 
severe fibrosis, the breast tissue behaves as a serial organ and that the maximum RT 
dose is the best predictor of complication. The summative data of 1410 patients from 
an independent dataset with six radiotherapy dose levels was found to have a good fit 
to both the LKB and Niemierko models (figures 4 and 5).  
 
Two other published studies have suggested a weak volume effect. However, one was 
based on a tumour bed boost using brachytherapy and other was based on summative 
patient data. The Alexander et al. study
79
 indicating a large volume effect has major 
limitations. To our knowledge, this is the largest dose-volume study for breast fibrosis 
using individual patient data. Parameter correlation leads to uncertainty in the 
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estimation of those parameter, independent of the size and diversity of the dataset
84
. 
An effective method to decrease the uncertainty is fixing one or more of the model 
parameters. Hence the α/β was fixed as 3Gy in this study based on the previously 
published literature
16
. There is no evidence to suggest the superiority of one model 
(LKB or Niemierko) over another
85
. However, similar values of the estimated 
parameters from the two models strengthen the results of this study.  
 
There are several possible reasons to explain the difficulty in demonstrating a volume 
effect for breast fibrosis, and can be considered limitations to the current study. Breast 
fibrosis may represent a focal effect, with the maximum radiotherapy dose as the most 
predictive factor of that focal effect. It is also possible that current scoring methods 
for breast fibrosis are not sensitive to the volume effect. Breast fibrosis is often graded 
as mild to severe based on the severity; however the scoring system does not take into 
account the extent of fibrosis e.g. a small discrete region of fibrosis and a widespread 
region of fibrosis are potentially scored alike. It has been suggested that NTCP 
parameters are influenced by the severity of the measured toxicity
86
. For rectum, 
Rancati et al. estimated the best fit „n‟ parameter was 0.23 for ≥ grade 2 rectal 
bleeding, which decreased to 0.06 when only severe rectal bleeding (grade 3) was 
considered
86
. It is plausible that a volume effect for breast tissue may have been seen 
for mild fibrosis, but this endpoint was considered to be of less clinical significance 
and therefore not assessed.  
 
Other toxicity endpoints like photographic assessment of breast shrinkage may also be 
more sensitive to the volume effect as it represents an affect across the whole organ 
effect, is more objective and scored independent of surgical changes. The current 
study only focused on breast fibrosis measured using photographic assessment, as 
patient reported scoring was not available for the majority of the patients included in 
the study. 
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Conclusions  
Modelled NTCP parameters suggest that for moderate and severe fibrosis, the breast 
tissue behaves as a serial organ and that the maximum RT dose is the best predictor of 
complication. The derived model, predicts close to zero effect of volume of irradiated 
tissue on the risk of toxicity. Evidence of a volume effect reported in the literature, 
warrants further investigation (Chapter 2). Further work will use IMPORT high 
toxicity and dosimetry data to test model parameters using similar methodology to 
that reported here.     
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Chapter 4 – A multi-institutional investigation of image guided radiotherapy for 
breast cancer 
 
This chapter addresses the main research objective of the study: the difference in 
spatial accuracy between IGRT and standard imaging. Differences in daily set-up 
errors measured using IGRT and standard imaging were assessed and overall accuracy 
was defined as the difference in population systematic set-up error obtained using 
IGRT compared to standard imaging. This chapter also addresses two secondary 
objectives, the decrease in safety margin provided by IGRT and the time required to 
perform IGRT and standard imaging verification.  Differences between centres and 
imaging modalities are also investigated.  
 
 
Introduction 
 
The breast radiotherapy process can be divided into three steps: 
 
1. Simulation – A planning computer tomography (CT) scan is performed while 
the patient is in the position that will be used during radiotherapy treatment delivery. 
The patient is immobilised using breast board/vacuum bag and pre-defined tattoo 
marks are placed on the skin surface. 
 
2.  Radiotherapy planning – The planning CT scan is used to identify and contour 
the target volumes (tumour bed and whole breast) and organs at risk (lung, heart, 
contralateral breast). Radiotherapy beams are designed to optimally cover the target 
volumes and spare the organs at risk. 
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3. Treatment verification and delivery – Radiotherapy treatment is delivered over 
a series of sessions (called fractions), to allow preferential DNA repair to take place in 
normal cells but not the cancerous cells. Before each radiotherapy fraction, the patient 
position is reproduced using laser light beams; pre-defined tattoo marks on the 
patient‟s skin are aligned with the lasers. Verification images are taken while the 
patient is on the treatment couch to confirm correct positioning and treatment is 
delivered. 
 
A difference in patient position between the planning CT scan and treatment session 
can lead to geographical miss of the target, potentially increasing the risk of cancer 
recurrence. Due to the uncertainty in patient and target position with each fraction 
(subsequently called as set-up errors), a planning target volume (PTV) margin is 
routinely added around the target volume. This PTV margin not only accounts for the 
daily interfraction and intrafraction motion (figure 6), but also beam penumbra and 
other geometrical uncertainties associated with the radiotherapy equipment. 
Interfraction motion includes differences in patients positioning between radiotherapy 
fractions. Intrafraction motion includes movement that occurs during each 
radiotherapy fraction, for example respiratory motion and tissue deformation.  
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Figure 6: Set-up errors and PTV margin in radiotherapy 
 
Pre-defined skin tattoo marks and laser beams are currently used to position patients 
for breast radiotherapy. Though simple to use, the set-up errors using this technique 
are large. Studies have reported that positional error using surface markers could 
range from 1-30 mm
87-89
. These large positional errors mean that a relatively large 
PTV margins has to be used (commonly 10 mm). 
 
Due to the addition of a large PTV margin, a considerable volume of the healthy 
surrounding tissue is unnecessarily irradiated to treatment dose, increasing the risk of 
radiation related adverse events. It also limits our ability to safely escalate the 
radiation dose to the target. IGRT technique can be used to reduce both interfractional 
and intrafractional errors and potentially reduce the PTV margins. 
 
A B C 
A. Target volume requiring radiotherapy dose 
B. Day to day variation in position of the target volume 
C. Safety margins (black arrows) around the target volume to account for positional 
errors and create a planning target volume (PTV)  
 76 
 
Megavoltage portal imaging method (2D-MV) is the current standard imaging 
verification technique for breast radiotherapy. The breast radiation treatment is 
usually carried out using lateral and medial tangential beams and these high energy 
(megavoltage) treatment beams are used to generate portal images (PI). The position 
of the ribs and lung on PI are compared to a digitally reconstructed radiograph (DRR) 
generated from planning CT images to identify the day to day variation in patient 
positioning (figure 7).   
 
Figure 7: Standard verification technique compares digitally reconstructed 
radiograph and mega-voltage portal image 
 
Parameters including central lung distance (CLD), defined as distance between the 
posterior field edge and the interior chest wall at the central axis and cranio-caudal 
distance (CCD), defined as distance between skin and the caudal beam edge are 
compared between the PI and DRR, to calculate positional errors in both the 
transverse and longitudinal direction (figure 8). If the positional errors exceed pre-
  
Digitally reconstructed radiograph (DRR) 
from planning CT scan 
Megavoltage Portal Image (PI) 
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defined limits (commonly set as 5mm), the patient is re-positioned before the next 
treatment is delivered.  
 
 
3.2. 
 
Figure 8: Measurement of central lung distance (CLD) in black and cranio-caudal 
distance (CCD) in blue on a DRR 
 
Though simple and effective, the portal images (PI) provide information about 
patients position based on bony anatomy, and not the breast tissue. In addition, the 
tumour bed (area at highest risk of cancer recurrence) cannot be directly visualised on 
the PI. The chest wall is used as a surrogate for the breast and the tumour bed.  
 
In recent years, studies have shown that bony anatomy (chest wall) is a poor surrogate 
for both the tumour bed and the whole breast. Hasan et al.
9
 study of 27 patients treated 
with accelerated partial breast irradiation indicated that (a) whole breast can move 
Central lung 
distance (CLD)  
Cranio-caudal 
distance (CCD) 
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independent of bony anatomy and (b) tumour bed can also move independent of the 
whole breast.  
 
Due to our inability to directly visualise the tumour bed for positional verification and 
correct for intrafraction motion, a PTV margin of 10 mm is commonly added to the 
tumour bed, to generate a planning target volume (PTV) for photon tumour bed 
boost
90
. 
 
Due to the additional PTV margin around the tumour bed, a large volume of normal 
breast tissue is treated to a high radiation dose. This can potentially increase the risk 
of late breast tissue toxicity. Apart from ipsilateral breast, an increase in PTV margin 
will also increase the radiation dose to contralateral breast, heart and ipsilateral lung. 
If we could safely reduce set-up errors, PTV margins around the tumour bed can also 
be safely reduced. This is desirable to reduce the risk of late breast and other normal 
tissue toxicity. 
 
The British Association of Surgical Oncology (BASO) have recommended that all 
patients undergoing breast conserving surgery should have surgical clips on the wall 
of the tumour bed
91
. Clips are currently used as fiducial markers, for the accurate 
localisation the tumour bed
92
. In addition, clips have been shown to be a better 
surrogate for the tumour bed compared to bony anatomy and used for IGRT
6,9,93
 In 
this report we call this approach clip-based image guided radiotherapy or clip-based 
IGRT. 
 
The use of surgical clips as a surrogate for the tumour bed was evaluated in 28 
patients by Weed et al.
6
. Each patient underwent two planning CT scans on separate 
days. The tumour bed and clips were identified as regions of interest (ROI). The scans 
were then fused based on bony anatomy and the displacement of the tumour bed was 
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compared to the displacement of the clips over time. The study found that the 
displacement of clips tracked the displacement of the excision cavity during radiation 
therapy. An average displacement error of 3mm was seen between the two ROIs, 
which were attributed to the finite thickness of the CT slices and use of limited 
number of clips. Hasan et al.
9
 also demonstrated that surgical clips are a better 
surrogate for tumour bed compared to bony anatomy and breast surface. Twenty 
seven patients underwent two CT scans in treatment position, one initial planning CT 
scan and a second scan at an average of 27 days after the first scan. The centre of 
mass (COM) of the lumpectomy cavity was determined on both CT scans for each 
patient. Localisation of the tumour bed was performed using CT registration of the 
following: bony anatomy, COM of surgical clips embedded in the excision cavity and 
breast surface. The distance between COMs using the three registration process were 
compared (ΔCOM bony anatomy, ΔCOM clips and ΔCOM breast surface). It was observed that 
localisation of the tumour bed using surgical clips is most accurate compared to 
localisation using bony anatomy and breast surface. Topolnjak et al.
93
 compared the 
residual error (surrogate error) between excision cavity and surgical clips placed in 
the excision cavity to determine if surgical clips are a good surrogate for the tumour 
bed and quantify the stability of the clips position. Twenty one breast cancer patients 
were treated with 28 fractions and cone beam CT (CBCT) scans were regularly 
acquired for set-up correction protocol. The CBCT scans were registered to the 
planning CT scan using grey value registration of the excision cavity and chamfer 
matching of the clips. The study showed that surgical clips are a good surrogate for 
excision cavity with small residual errors of 0.7-1.3 mm. 
 
It is now known that surgical clips are a better surrogate of the surgical cavity (tumour 
bed), as compared to bony anatomy. A number of studies have evaluated the 
feasibility of using these surgical clips for image guided breast radiotherapy
94-96
. 
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The IMPORT HIGH trial group used gold fiducial markers (small metallic seeds that 
can be sutured on to the cavity wall) as a tumour bed surrogate for IGRT to estimate 
safe PTV margins around the breast tumour bed
94
. Treatment verification and daily 
on-line correction were performed on 42 patients with 2D-MV (high energy) portal 
image or kV (low energy) planar image or cone beam CT. The study concluded that 
using extended no action level (e-NAL) or daily on-line correction strategy (discussed 
later), the tumour bed PTV margins can be safely reduced to 5mm. Leonard et al.
95
 
also demonstrated the feasibility of gold seed fiducial markers for marker-based IGRT 
using orthogonal and lateral MV portal films in 20 patients. 
 
2D-MV portal imaging verification method using bony anatomy is relatively simple 
and easy to use whereas additional verification time and resources are required for 
marker-based IGRT technique. The benefit of clip-based IGRT over portal imaging 
needs to be quantified by comparing the PTV margins and verification time for both 
techniques. In addition, most of the feasibility studies of fiducial marker-based IGRT 
were based on small number of patients, using gold seeds as fiducial markers. The use 
of gold seeds as fiducial markers is quite expensive (~£200/patient), considering that 
breast radiotherapy constitutes a large part of radiotherapy department work load. 
Titanium clips can be used as an alternative fiducial marker (~£1/patient), though due 
to their low density, they cannot be visualised on 2D-MV portal image. Several 
different imaging modalities can be used for titanium surgical clip-based IGRT: kV 
planar images, kV Cone beam CT and Mega Voltage CT (TomoTherapy). It is 
currently unclear if the PTV margin will depends on the type of IGRT imaging 
modality used.  
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Materials and Methods 
 
The sample size calculation was carried out by the ICR-CTSU. The study statistician 
(JH) was responsible for overseeing all statistical analyses. In this study, the primary 
research objective was the accuracy of clip-based IGRT compared to standard 
imaging.  This study proposed to use accuracy to determine two secondary research 
objectives of this study, volume of normal tissue irradiated and the probability of 
adverse effects (fibrosis) using the following steps:  
 Accuracy is calculated using the mean set-up error for each patient (patient 
systematic error). The mean set-up error for each patient is the mean of the 15 set-
up errors measured at each fraction. The accuracy of standard imaging compared to 
clip-based IGRT will determine the additional safety margin.   
 The technique-specific safety margin is calculated from the distribution of the 
patients‟ overall set-up errors. The size of the margin is approximately two and a 
half times the standard deviation of the mean set-up errors for all patients 
(population systematic error).
97
 
 The volume of normal tissue irradiated when standard imaging is used is then 
calculated by simply adding this margin to the treatment volume used for IMPORT 
high (which uses clip-based IGRT).  
 The probability of adverse effects (fibrosis) for clip-based IGRT and standard 
imaging will be determined from the volumes of tissue irradiated with each of 
these methods and using the relationship between incidence of fibrosis and volume 
determined using radiobiological modelling.  
 
This study was designed to generate two sets of data: the mean set-up error from n 
patients receiving curative breast radiotherapy using clip-based IGRT and using 
standard imaging.  
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A difference in the standard deviation (or variance) of these data sets will result in a 
difference in safety margin and the volumes of normal tissue irradiated. Thus, the 
sample size calculation was based on finding a significant difference in the variance 
of these two data sets. To perform the sample size calculation the standard deviation 
of set-up errors for IGRT and standard imaging the correlation between the data-sets 
was estimated using evidence from the literature:  
 Standard deviation: From a small study of 20 patients, Topolnjak et al.98 found 
that, if standard imaging were used daily, the standard deviation of the set-up 
errors was between 2.7mm and 3.8mm. In a similar study of 10 patients by Kim et 
al.
96
 the standard deviation of set-up errors was measured to be between 0.9 mm 
and 1.4 mm when daily clip-based IGRT is used. Kim et al. estimate that this range 
of values rises from 2.2mm to 2.6mm when other factors such as deformation of 
the breast are taken into account. To calculate the sample size, based on these 
studies the aim was to detect differences in standard deviations corresponding to a 
decrease from 3mm for standard imaging to 2mm for clip-based IGRT.  
 Correlation: Because no similar studies have previously been performed directly 
comparing clip-based IGRT and standard imaging the correlation between the two 
data sets is unknown.  Work by Penninkhof et al.
99
 shows that set-up errors 
measured in the same patient using two imaging techniques to image bony 
anatomy are highly correlated (~0.85). It was expected that the correlation between 
set-up errors for clip-based IGRT and standard imaging is high (> 0.5) as they will 
be measured in the same patient but not as high as for two techniques measuring 
bony anatomy (i.e. < 0.85).  
 
The sample size required was determined for high correlation, 0.7 and very low 
correlation, 0.1.  Using computer simulations based on Fisher's test
100
, the number of 
patients required to detect a 1mm difference in the standard deviations from 2mm to 
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3mm assuming correlation=0.7, power=80%, alpha=0.05 was determined.  Using the 
same analysis but assuming very low correlation (correlation = 0.1), with 250 patients 
it was found that it was possible to detect the same difference (2mm v. 3mm) in 
standard deviations (power=80% and alpha=0.05).   
This sample size calculation was based upon estimates from studies using small 
numbers of patients and a definitive value for the correlation between set-up errors 
measured using the two techniques was not available.  We based the study on the 
requirement for a larger cohort of patients, 250 which allows for smaller correlations. 
It was proposed that an Independent Data Monitoring Committee confidentially 
review the data after the first 100 patients, and advise on the final sample size.   
 
All patients participating in the national Phase 3 IMPORT HIGH trial have surgical 
clips inserted into the walls of the TB and are receiving clip based IGRT as routine. 
The daily verification image data for IGRT were used to calculate the set up error 
with clip-based technique. These imaging data were also used to calculate the set up 
error if bony anatomy was used for verification (ignoring the information from the 
clips). All patients had previously consented for their imaging data to be used for 
research purposes. As the imaging data was retrospectively analysed, it had no direct 
impact on the study population. 
 
  
Imaging data was collected from five different centres participating in the IMPORT 
HIGH trial: Addenbrookes Hospital, Royal Marsden Hospital (RMH), Ipswich 
Hospital, Cheltenham Hospital and Clatterbridge Hospital. The 5 centres were chosen 
because they were early implementers and high recruiters of the IMPORT high trial. 
Combined, these 5 centres used all 3 imaging techniques used in the IMPORT trial 
which represented current national practice. Ipswich, Cheltenham and Clatterbridge 
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centres used KV planar images (2D-kV) and daily on-line image verification protocol, 
RMH used Cone beam CT (kV-CBCT) with an e-NAL verification protocol, and 
Addenbrookes used Mega Voltage CT (MV-CT) (TomoTherapy) with daily on-line 
image verification protocol for treatment verification and positional correction (figure 
9). The details of different image verification protocols (IVPs) are discussed later.  
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MVCT (TomoTherapy) 
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Figure 9: Bony anatomy and clip based verification using kV-CBCT, MVCT and 2D-
kV  
 
Bony anatomy (BA) based set-up errors were measured using automatic bony 
anatomy registration software for kV-CBCT (Synergy, Elekta Ltd, Crawley, UK) and 
manually for MV-CT and 2D-kV. Then clip-based IGRT set-up errors were measured 
by manually adjusting alignment of images from their BA-matched position. BA set-
up errors (SBA) and clip set-up errors (Sclip) in the lateral (LR), superior-inferior (SI) 
and anterior-posterior (AP) directions were recorded. The time taken to perform bony 
anatomy (TBA) and clips (Tclips) based image assessment (a secondary objective of this 
study) were also recorded. Only images with sufficient information on bony anatomy 
were used. Intra- and inter-observer errors were assessed using nine images from three 
patients and a minimum of two observers. 
 
For RMH patients, e-NAL corrections applied for actual treatment were removed 
from the measured set-up errors so that the effects of various IVPs could be studied.  
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Radiotherapy positional errors are classified into systematic errors and random errors. 
Systematic errors occur if the mean irradiation geometry in a fractionated treatment 
differs from the geometry of the treatment plan. Fraction to fraction variation around 
the mean deviation is called as random error. Systematic error can shift the 
cumulative dose distribution relative to the target and contributes more towards the 
PTV margin as compared to random error which blurs the dose distribution. 
 
The PTV margin calculation is based on the population systematic error (∑) and the 
population random error (σ). 97 
 
PTV margin = 2.5 ∑ + 0.7 σ     (8) 
 
For a given population, systematic error (∑) is the mean of the standard deviation 
(SD) of all patients‟ mean set-up errors and random error (σ) is root mean square of 
the all patients‟ SD of daily errors.  
 
For this project, verification images of the study population were used to measure the 
distance of bony anatomy (BA) and clips (IGRT) from a reference position to 
determine bony set-up error (SBA) and clip set-up error (Sclips). The additional PTV 
margin required if standard bony anatomy verification technique is used over clip 
based IGRT was calculated using the difference in the distance between bony 
anatomy and clip position. For each patient Delta error, SDIFF = SBA – Sclips was 
generated. The mean and SD of the SDIFF, SBA  and Sclips  for the study population was 
used to generate the systematic error (delta ∑) and random error (delta σ) for the 
margin formula.  
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SDIFF for the first 112 patients was collected and analysed to calculate the required 
sample size. The calculations were based on the 95% confidence interval (CI) that 
will give the required precision of 0.05 cm on the PTV margin estimate.  
 
Individual patient and population mean error (M), systematic (∑) and random (σ) 
errors were calculated for bony anatomy (standard imaging) and clips (clip-based 
IGRT) error data. Bland-Altman analysis, least squares linear regression and 
calculation of the Coefficient of determination (R
2
) between SBA and Sclips were also 
performed. 
 
As the tumour bed has previous received background radiation during whole breast 
irradiation, the margin formula was modified by reducing the contribution of the σ 
error. 
 
PTV margin = 2.5 ∑ + 0.3 σ      (9) 
 
 
The PTV margins required for safe treatment may not only depend on the method of 
verification used (standard imaging using bony anatomy or clip-based IGRT), but also 
on the type of verification protocol used. Four different verification protocols were 
investigated to calculate the PTV margins: 
1. No correction protocol – No imaging is undertaken and patient is positioned 
using laser based set-up. 
2. No action level (NAL) – The systematic error is calculated after 3 treatment 
fractions and systematic set-up error is corrected for all subsequent fractions, 
regardless of the magnitude of the error
97
. 
3. Extended-no action level (e-NAL) - The first stage of the protocol follows 
NAL strategy with additional once weekly verification and correction
101
. 
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4. Daily correction protocol - Patient position is verified daily against the 
planning CT scan and corrected (if required). 
 
SBA and Sclips data was not available for all 15 treatment fractions. In order to evaluate 
the effect of IVPs for a 15 fraction treatment, a simulation of set-up errors was 
performed. For each patient, if N was the total number of images analysed, in cases 
with N < 15, a normal distribution with mean and standard deviation equal to the 
patient‟s real set-up data was sampled N-15 times. Combined real and simulated 
patient set-up data were used to simulate the IVPs using Matlab (Mathworks, Natick, 
MA, USA). The smallest number of images available per patient was N=5. To test if 5 
images was adequate to describe a patient‟s set-up data, the mean and standard 
deviations of set-up errors of 28 patients with N = 15 were determined, for all 15 set-
up errors and 5 set-up errors (fractions 1, 2, 3, 7 and 11). When using 5 images 
compared to 15 images, mean difference in patient‟s mean and standard deviation of 
set-up errors was 0.006 cm and 0.013 cm, respectively. 
 
Having obtained 15 measures of set-up error for each patient, these data were used to 
simulate the effect of different IVPs on set-up errors, and hence PTV margins. 
Simulated IVPs included: on-line BA (OLBA), on-line clip (OLclips), e-NAL BA (e-
NALBA) and e-NAL clip (eNALclips). Post IVP simulation, any remaining systematic 
and random errors were calculated for the patient population. Set-up error simulation 
and error calculation was repeated 1000 times for each IVP. Error values from repeat 
simulations were averaged to give more precise results giving less than 0.1% 
uncertainty (1 SD) from random sampling. 
 
This study used clips as a surrogate for the tumour bed. Surrogate systematic and 
random errors of 1.1mm were added in quadrature to the set-up errors
96
, to account 
for the uncertainty introduced by the localisation of clips rather than the tumour bed. 
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  (10) 
 
As discussed before, 2D–MV portal imaging is the current standard treatment 
verification method for breast radiotherapy. No portal imaging data was collected as 
part of the study. The 2D-MV set-up error data (S2D-MV) were derived from SBA using 
the method previously proposed by Topolnjak et al.
98
 
 
S2D-MV = sBA +  + rand x η     (11) 
 
Where parameters  (slope) and  (intercept) were determined from regression 
analysis, η is the standard deviation of the differences between 2D-MV and kV-CBCT 
set-up errors measured by Topolnjak et al.
98
 and rand is a random number sampled 
from a normal distribution.  
 
Tangential portal imaging will not provide a measure of set-up error in all three 
ordinal directions.  It was assumed that 3D set-up errors are available from 2D-MV 
imaging, which is possible if anterior and lateral portal images are used
102
.  
 
In this study, for the LR and AP directions,  = 0.82,  = 0.66 mm and η = 0.18mm 
were used. For the SI direction  = 0.43,  = -0.28 mm and η = 0.32mm were used98. 
Bony anatomy based IVP simulation was repeated using S2D-MV. 
 
Statistical Analyses: Data were tested for heterogeneity between imaging techniques 
and radiotherapy centres. All data were tested for normality using the Shapiro-Wilk 
test. Shapiro-Wilk tests indicated some data were not normally distributed.  Overall 
patient mean SDIFF  was tested for significant difference from zero using a one-sample 
Student‟s t-test. For SDIFF, the difference in absolute SDIFF between centres and imaging 
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techniques was tested using Kruskal-Wallis followed by sensitivity analysis.  
Differences in overall mean patient systematic error M, population systematic error  
and population random error  between modalities, centres and imaging protocols 
were tested.  For M, difference from zero was calculated using one-sample Student‟s 
t-test (all data) or Wilcoxon signed-rank test (per centre). For , Non-Parametric 
Levene‟s test (NPLT) was used to test difference in the variance of mean patient 
errors.  For ,  Kruskal-Wallis test was used to test for differences in patient‟s random 
errors.  For all tests, data were considered to be significantly different if p < 0.05.  
Sensitivity analysis was performed by removing data from one centre at a time and 
repeating tests using Holm-Bonferroni correction. The time required for positional 
verification between IGRT and standard imaging was compared using Wilcoxon 
Signed Ranks Test. 
 
 
 
 
 
Results 
 
Study sample size calculation: Using computer simulations based on Fisher's test
100
, 
with 128 patients, it was possible to detect a 1mm difference in the standard 
deviations from 2mm to 3mm assuming correlation=0.7, power=80%, alpha=0.05; 
using the same analysis but assuming very low correlation (correlation = 0.1), with 
250 patients it was possible to detect the same difference (2mm v.s. 3mm) in standard 
deviations (power=80% and alpha=0.05).   
 
Bony set-up error (SBA) and clip set-up error (Sclips) of 112 patients from three 
different centres were initially collected for the review of the sample size. 
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The additional margin required if standard imaging verification is used instead of clip-
based IGRT was calculated from SDIFF in left-right (LR), superior-inferior (SI) and 
anterior-posterior (AP) directions. These results are summarised for the three centres 
in table 5. 
 
 
Centre Mean (cm) Variance (cm) Margin (cm) 
 LR SI AP LR SI AP LR SI AP 
ALL -0.02 -0.03 -0.03 0.039 0.043 0.044 0.54 0.59 0.59 
CCC 0.03 0.03 0.01 0.043 0.030 0.022 0.56 0.50 0.42 
ADD 0.00 0.02 -0.01 0.018 0.035 0.032 0.38 0.56 0.51 
RMH -0.03 -0.06 -0.04 0.044 0.046 0.052 0.57 0.60 0.63 
The variances of SDIFF in the 3 directions for all centres were: 
 
Table 5: Mean and Variance of SDIFF for all 112 patients and individual centres. 
(Highlighted data were used in the sample size calculation)  
 
 
SDIFF
2
LR = 0.039, SDIFF
2
SI = 0.043 and SDIFF
2
AP = 0.044  (12) 
 
Taking the largest variance SDIFF
2
AP = 0.044, the 95% confidence interval (CI) was 
calculated from the chi-square distribution table using the following: 
  
Lower limit =(n-1) SDIFF
2
/ χ2L    to   Upper limit =(n-1) SDIFF
 2
 / χ2U (13) 
 
Where χ2U = upper 2.5% point of χ
2
 distribution for 111 degrees of freedom = 83.735  
And χ2L = lower 2.5% point of χ
2
 distribution for 111 degrees of freedom = 142.049 
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Hence 95% CI for variance is 0.344 (111 x 0.044/142.049) to 0.0583 (111 x 
0.044/83.735) and the 95% CI for standard deviation = 0.1855 (√0.344) to 0.2415 
(√0.0583). Based on this calculation, there was 95% confidence that the margin lies in 
the region of 0.4637cm to 0.6037cm (SD x 2.5). This is an overall width of 0.140cm. 
 
As the overall precision required was 0.05 (overall width of 0.1cm), the above 
formula was applied for different sample sizes and produced an estimate that a sample 
size of 200 patients would be required for this study. 
 
The bony anatomy set-up error (SBA) and clip set-up error (Sclips) for 218 patients from 
five different centres was collected. Each centre uses a different imaging technique as 
summarised below in table 6. 
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Hospital Centre Imaging modality No of 
patients 
Royal Marsden Hospital (RMH) A Cone Beam CT 
(CBCT) 
79 
Addenbrookes (ADD) B MV-CT 
(TomoTherapy) 
40 
Clatterbridge Cancer centre (CCC) C 2D-kV Planar 
images 
39 
Cheltenham (CHE) D 2D-kV Planar 
images 
30 
Ipswich (IPS) E 2D-kV Planar 
images 
30 
 
Table 6: Summary of imaging technique and patient accrual for each centre  
 
The intraobserver and interobserver errors were less than 1.4mm for all three imaging 
modalities. No significant difference was seen in inter-observer errors between the 
five centres (ANOVA, p=0.34). The overall mean error was found to be significantly 
different from zero for Addenbrookes (centre B) and Ipswich (centre E). At 
Addenbrookes, this is due to couch sag associated with Tomotherapy
103
. The Ipswich 
centre is investigating the cause of their non-zero mean error. 
 
The systematic errors (∑) and random errors (σ) using bony anatomy verification and 
titanium clips based verification were mostly 2-4 mm across all centres. Individual 
centre and overall errors are summarised in table 7. Individual patient systematic error 
using bony anatomy and surgical clips are compared in figure 10 using Bland-Altman 
analysis.  The bias and limits of agreement (1.96SD) between BA and clip 
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systematic errors were 0.00.21 cm, 0.00.26 cm and 0.10.22 cm in the LR, SI and 
AP directions, respectively.  Using linear regression analysis to compare bony 
anatomy and surgical clips systematic errors, the coefficient of determination (R
2
) 
were 0.57, 0.42 and 0.82 in the LR, SI and AP directions respectively, suggesting that 
bony anatomy based verification underestimates the patient systematic error by up to 
23% compared to clips based verification. The difference in set-up errors using bony 
anatomy and clips (∑DIFF and σDIFF) for individual centres and all patients are 
summarised in table 8.  
 
The time required to perform bony anatomy (TBA) and clips (Tclips) based image 
assessment are also summarised in table 8. If all centres and all imaging techniques 
were considered there was no significant difference between (TBA) and clips (Tclips) 
(Wilcoxon Signed-Rank, p = 0.36). The ranges in times were 8 s to 240 s for clip-
based IGRT image assessment and 8 s to 178 s for bony anatomy image assessment.  
 
The time required for image assessment varied with the type of imaging modality 
used. For all centres using 2D-kV modality, TBA was greater than Tclips (Wilcoxon 
Signed-Rank Test, p<0.001). In contrast, centre “A” using kV-CBCT found median 
time Tclips > TBA , 92 seconds versus 26 seconds respectively (Wilcoxon Signed-Rank 
Test , p< 0.001). No significant time difference was found for MVCT (Wilcoxon 
Signed-Rank Test, p = 0.92).  The time to perform both clip and bony anatomy based 
image assessment varied significantly between the 3 centres using 2DkV imaging 
(Kruskal-Wallis, p<0.001). Using sensitivity analysis, it was found that centre C 
required significantly shorter time to match both clips and bones, compared to centres 
D and E.   
 
There was a small but statistically significant difference in the difference between 
standard imaging and clip-based IGRT set-up errors (delta errors) between centres 
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(Kruskal-Wallis, p<0.05). The smallest delta error, SDIFF, was seen for centre B using 
MVCT and the largest delta error was seen for centre C using 2D-kV (Table 8). Using 
the Kruskal-Wallis test,  a significant difference between  delta errors was seen 
between different centres in the LR and SI direction (p<0.05). No significant 
difference between in delta error was seen among centres using 2D-kV imaging 
modality. Non-Parametric Levene‟s test and Bartlett‟s box test also indicated non-
homogeneity of variance among centres (table 9).  After excluding data of patients 
with MV-CT imaging, the variance of delta error were similar between centres.
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Centre No. 
Patients 
Total 
Number 
of images 
Bony Anatomy 
Random Error  BA 
(cm) 
Bony Anatomy 
Systematic Error  BA 
(cm) 
Clips 
Random Error  clip 
(cm) 
Clips 
Systematic Error  clip 
(cm) 
   LR SI AP LR SI AP LR SI AP LR SI AP 
ALL 218 1574 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 
 
A (kVCBCT) 79 504 0.3 0.3 0.3 0.2 0.3 0.3 0.3 0.3 0.3 0.3 0.2 0.3 
B (MVCT) 40 200 0.4 0.3 0.4 0.3 0.2 0.4 0.4 0.3 0.5 0.3 0.2 0.4 
C (2D-kV) 39 510 0.3 0.4 0.2 0.4 0.3 0.1 0.3 0.3 0.3 0.3 0.3 0.2 
D (2D-kV) 30 180 0.3 0.4 0.3 0.2 0.3 0.3 0.3 0.3 0.3 0.2 0.2 0.2 
E (2D-kV) 30 180 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.3 0.4 0.3 0.3 0.3 
 
Table 7: Systematic and random errors using bony anatomy and clip verification for each centre and for all centres 
combined
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Figure 10: Bland-Altman plots of average of bony anatomy and clips mean set-up error versus difference between mean 
clip set-up error mean bony anatomy set-up error in the LR, SI and AP directions.  Solid line indicates mean difference 
between mean clip and mean bony anatomy set-up errors (the bias) and the dotted lines represent the limits of agreement 
(1.96SD).  
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Centre Delta Error (SDIFF) 
Mean Absolute Delta (range) 
(cm) 
 
Time 
Median (range) 
(seconds) 
 LR SI AP 3D  T bony anatomy T clip 
ALL 0.20 (0,1.7) 0.26 (0,3.2) 0.21 (0,2.0) 0.32 (0,10.2) 73 (8, 240) 66 (8,178) 
 
A (kV-CBCT) 0.19 (0,0.7) 0.24 (0,3.2) 0.22 (0,1.7) 0.28 (0,10.2) 26 (8,51) 92 (11,177) 
B (MVCT) 0.14 (0,0.7) 0.12 (0,1.2) 0.18 (0,1.3) 0.17 (0,2.0) 102 (70,230) 110 (25,178) 
C (2DkV) 0.23 (0,1.7) 0.29 (0,2.4) 0.20 (0,2.0) 0.38 (0, 6.29) 22 (20,76) 16 (8,52) 
D (2DkV) 0.21 (0,1.3) 0.32 (0,1.3) 0.21 (0,1.0) 0.35 (0,2.2) 79 (60,154) 28(20,85) 
E (2DkV) 0.20 (0,1.5) 0.31 (0,1.4) 0.23 (0,1.0) 0.36 (0,3.3) 110 (28,240) 34 (16,120) 
 
Table 8: Delta errors (difference between bony anatomy and clips, SDIFF) in the LR, SI and AP directions and the 
magnitude of their 3D vector. Time required for image matching with both techniques has also been summarised 
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P-Values LR SI AP 
All centres 0.00 0.00 0.22 
2D-kV (CCC,CHE,IPS) 0.67 0.79 0.93 
2D-kV & kV-CBCT 
(RMH,CCC,CHE,IPS) 
0.85 0.05 0.92 
 
Table 9: Test of homogeneity of variances of delta errors from all centres, those using 
techniques 2D-KV technique and after excluding the centre using MV-CT 
 
The PTV margins should be estimated using a sample group which is representative 
of the whole population. In view of significant heterogeneity using MV-CT, set-up 
data of centre B (n=40 patients) were not included in the simulations of PTV margin 
estimation. Based on the set-up data of 178 patients, the overall width of 95% 
confidence interval on the PTV margins is ~0.107 cm giving a precision of ± 0.05 cm. 
 
The mean (M), systematic (∑) and random (σ) residual error were calculated using the 
following image verification protocols (IVP): 
a. No correction protocol -  NO IMAGING 
b. Extended- no action level using bony anatomy- e-NALBA  
c. Extended- no action level using clips - e-NALclips 
d. Daily correction protocol (On line correction) using bony anatomy - OLBA 
e. Daily correction protocol (On line correction) using clips – OLclips 
 
The results are summarised in table 10.  When using 5 images compared to 15 images, 
mean difference in patient mean and standard deviation of set-up errors was 0.006 cm 
and 0.013 cm, respectively. 
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In all cases, the variation (1 SD) in residual errors due to random sampling was less 
than 0.01 mm. Residual systematic and random errors were smaller for clip-based 
verification as compared to BA verification, irrespective of the IVP method.  
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IVP M(cm)  (cm) (cm)  
 LR SI AP LR SI AP LR SI 
 
AP 
No Imaging -0.06 0.00 0.00 0.34 0.30 0.34 0.27 0.25 0.32 
          
OLclips   
(2D-kV or kV-CBCT) 
0.00 0.00 0.00 0.20 0.20 0.20 0.05 0.05 0.05 
          
eNALclip   
(2D-kV or kV-CBCT) 
-0.01 0.00 0.02 0.30 0.30 0.32 0.08 0.07 0.10 
          
OLBA   
(2D-kV or kV-CBCT) 
-0.01 -0.01 -0.03 0.30 0.38 0.33 0.16 0.18 0.12 
          
eNALBA  
(2D-kV or kV-CBCT) 
0.00 0.01 0.05 0.32 0.35 0.32 0.19 0.23 0.19 
          
OLBA  (2D-MV) -0.64 0.27 -0.60 0.43 0.45 0.43 0.19 0.21 0.19 
          
eNALBA  (2D-MV) -0.45 0.21 -0.43 0.38 0.32 0.40 0.23 0.26 0.23 
 
   
Table 10: Mean, Random and Systematic errors using different image verification protocols 
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The study showed that for kV based imaging modalities, on-line IVP produces smaller errors 
than e-NAL for both clips and bones. Using, on-line BA based verification, systematic errors 
were larger than those for off-line clip based verification (e-NALclips), by up to 0.11 cm (Non-
Parametric Levene‟s Test (p-values <0.001). Off-line BA verification (e-NALBA) increased 
systematic error further by ~ 0.05cm (Non-Parametric Levene‟s Test p-values <0.001).  
 
2D-MV based image verification increased systematic error for both on-line and off-line 
protocols by an average of ~0.3cm (Non-Parametric Levene‟s Test, p<0.001). For off-line 
imaging of BA (e-NALBA), the difference between kV and 2D-MV was significant in the SI 
direction only. For 2D-MV imaging of BA, there were no significant difference in systematic 
errors between on-line and off-line IVPs (p=0.12).  
 
The overall mean error (M) for 2D-MV IVPs was non-zero (table 10).  This is likely due to 
the use of simulation technique to generate 2D-MV set-up errors and reflects the relationship 
between kV-CBCT and 2D-MV set-up errors. 
 
The estimated PTV margin using different IVPs are given in figure 11. Based on this study, a 
tumour bed boost PTV margin of 1 cm is required if no imaging modality is used. If standard 
bony verification technique is used (2D-MV), a PTV margin of 0.8cm is required. This can 
be reduced to 0.6 to 0.7 cm if 2D-kV/ kV-CBCT based bony anatomy verification is used. 
The use of clip-based verification (clip based IGRT) allows a 0.5cm boost PTV margin for 
both on-line and e-NAL protocols. 
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Figure 11. Tumour bed PTV margins required for the different imaging verification protocols 
considered in this study. Margins are given for the LR, SI and AP directions.  
 
Discussion 
 
This large multicentre multimodality study has compared the set-up errors of bony anatomy 
and clip based verification. It demonstrates that PTV boost margin of 5 mm are adequate if 
clip-based IGRT (2D-kV and kV-CBCT) is used both for on-line and off-line IVP. However, 
if standard portal imaging (2D-MV) is used, an increase in PTV margin of ~3mm is 
necessary. The major strengths of the study include its large patient cohort, use of different 
imaging modalities and direct comparison of bony anatomy verification against clip based 
verification. 
 
 In this study, the measured population random and systematic errors (for the TB) were 
within 2 to 4 mm, suggesting that a PTV margin of 10 mm is required if no IVP is used. 
Similar results have been reported by Topolnjak at el.
98
 who reported kV-CBCT measured 
systematic errors of 0.31, 0.38 and 0.25 cm in the LR, SI and AP direction respectively based 
on 20 patients. This current study found that the BA based verification underestimate 
patients‟ systematic error as compared to clip-based IGRT. Other authors have reported 
differences between set-up errors measured bony and clip using small patients‟ cohorts104-105.  
Gierga et al.
104
 used 2D-kV in 12 patients and reported a median 3D delta error of 0.54 cm, 
P
T
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upper and lower quartile values were 0.75 cm and 0.41 cm respectively. Fatunase et al.
105
 
reported a mean 3D delta error of 0.6 cm using kV-CBCT in 10 patients.  In the current 
study, 1379 images were analysed and the mean, median, and upper and lower quartile 3D 
vector difference between bones and clips (delta) were 0.35, 0.18, 0.06 cm and 0.41 cm 
respectively (table 8). This implies that the PTV margins of 5mm (as used in the IMPORT 
HIGH study) may be insufficient if BA is used as a surrogate for the tumour bed and a larger 
PTV margin of ~8mm is required if 2D-MV based bony anatomy verification (online and 
offline protocols) is used.  
 
Similar results have been reported by Penninkhof and colleagues
99
. Two orthogonal planar 
kV images and one 2D-MV portal image were acquired for 80 patients throughout their 
radiotherapy. Surgical clips based registration was performed on all kV images and set-up 
errors (systematic and random) were estimated for no correction protocol, NAL protocol and 
e-NAL protocol.  The 2D-MV portal images were independently registered with the DRR 
using lung contour and caudal side of the external breast contour for estimating 2D-MV set-
up errors.  
 
Time required for clip-based IGRT image assessment compared to standard imaging image 
assessment was imaging technique dependent. Clip-based IGRT verification was quicker than 
bony anatomy verification when using the 2DkV imaging.  For kV-CBCT, bony anatomy 
verification was quickest, this is most likely because automatic bone registration was used. 
Clip-based IGRT verification using MVCT took the greatest amount of time (mean >2 
minutes). This may be due to poor visualisation of clips on MVCT images.   
 
Centres‟ C, D and E had significantly different times for both clip-based IGRT and standard 
imaging. The differences may be explained by differences in observers; at centre C images 
were matched by a senior radiographer (AB), and at centre D by a physicist (EH) and a senior 
radiographer (RP) and at centre E by EH only.   
 
Overall, differences in median times between bony anatomy and clip verification for each 
modality were small, the greatest difference being 76 seconds, for kV-CBCT. IMPORT 
image data was obtained retrospectively and therefore no times for image data acquisition 
were available. This was a limitation of our study, however, bony anatomy (TBA) and clips (T 
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clips) based verification data are useful for any future cost-benefit analysis, which is beyond 
the scope of our study.  
    
 
Conclusion 
The work described in this chapter addressed the main objective of this programme of work, 
to compare the spatial accuracy of breast radiotherapy using clip-based IGRT and standard 
imaging during curative radiotherapy for early breast cancer.  The study concluded that 
accuracy of clip-based IGRT was greater than standard imaging for breast boost to the 
tumour bed. The use of three common imaging protocols (on-line, NAL and e-NAL 
correction protocols) with clip-based IGRT improved accuracy by between 2 to 4mm, 
compared to standard imaging.  Using no imaging protocol, the systematic set-up errors for 
tumour bed were 0.26 cm, 0.25 cm and 0.34 cm in LR, SI and AP direction respectively. 
Using standard imaging (2D-MV portal images) with the e-NAL correction protocol, the 
systematic set-up errors for tumour bed were 0. 23cm, 0.24 cm and 0.28 cm in LR, SI and AP 
direction respectively.  
 
Two secondary objectives were also addressed: the decrease in safety margin given by clip-
based IGRT and the time required to perform clip-based IGRT and standard image 
assessment.  Using IGRT safety (PTV) margins were decreased compared to standard 
imaging.  The study concluded that using clip based registration and the correction protocol, 
PTV a margin of ≤5 mm for the tumour bed is adequate. Time required for clip-based IGRT 
verification compared to bony anatomy (standard imaging) verification was technique 
dependent.   
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Chapter 5 – The effect of patient and treatment characteristics on set-up accuracy 
 
The work presented in this chapter uses data presented in chapter 4 and is directly related to 
the primary research objective. The study investigated differences in set-up accuracy using 
standard imaging between different patient groups, to determine if some patients may benefit 
more from IGRT than others.   
 
Introduction 
 
Treatment set-up errors, and hence PTV margins, may be influenced by characteristics of the 
patient and the treatment.  Examples of such characteristics include: breast size, tumour bed 
position and surgical closing technique. Also, it is possible that different patient groups may 
require different PTV margins which depend on the type of set-up used e.g. laser on skin 
marks or bony anatomy imaging. Currently uniform TB PTV margins are used across the 
whole patient population. If the type of imaging, and/or patient and treatment characteristics 
do influence the size of treatment set up errors then uniform margins may be sub-optimal. If 
margins are too large this results in the unnecessary irradiation of normal tissues and 
conversely, smaller PTV margins may lead to the risk of geographical miss of the TB.  
 
The aims of the study described in this chapter are to test whether a set of patient and 
treatment variables influence set-up errors and to explore the feasibility of individualised TB 
PTV margins in breast boost radiotherapy. 
 
Materials and methods 
 
Data from 218 patients, from the cohort described in Chapter Four, were used in this work. 
These data consisted of images plus a set of characteristics hypothesised by 5 clinical 
oncologists (MM, AK, RJ, CEC and JY) and one breast surgeon (AT) to have an effect on set 
up errors. These characteristics formed three groups: patient related, surgery related and 
treatment related. 
 
The image data from the whole cohort (n = 218) were used to calculate treatment set-up 
errors based on (i) a laser based set-up (no imaging) and (ii) a bony anatomy based set-up 
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(standard imaging). The population systematic errors (laser, BA) were calculated from the 
variance of the individual patients‟ systematic set-up errors. 
 
The patient, surgical and treatment characteristics are summarised in Table 11. Tumour bed 
locations were categorised into regions in the axial and sagittal plane as shown in Figure 12. 
Breast volume was obtained from the radiotherapy planning CT. Data on surgery: apposed 
(closed) or unapposed (open) cavity, and seroma were obtained from the surgical notes. A 
single radiation oncologist rated seroma visibility as not visible/subtle or easily visible and 
determined the presence of one or more clips placed at the posterior fascia and number of 
clips placed in the excision cavity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Schematic diagram to show (a) TB location viewed on axial CT slice (1(blue) 
=medial, 2(pink) =chest wall, 3(green) =anterior and 4(yellow) =lateral) and (b) TB 
location in the SI (superior-inferior) direction viewed on  sagittal CT slice (1 = superior, 2 = 
middle and 3 = inferior).  
 
 
(a) (b) 
1 
2 
3 
4 
1 
2 
3 
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Characteristics No. of patients 
with data in each 
group 
Total number of 
patients with 
data 
Median value 
Patient related:  
TB Axial Location (1/2/3/4) (See Figure 12.) 30/96/33/59 218  
TB SI Location (1/2/3) (See Figure 12.) 107/90/21 218  
Breast volume (above median/below median) 
(cm
3
) 
109/109 218 855 cm
3 
Surgery related: 
Seroma Visibility (not visible/ easily visible) 158/60 218  
Surgical Closing technique (closed/open) 113/88 201  
No. Clips  (above median/below median) 
 
109/109 218 6 
Clip in Posterior Fascia (no/yes) 40/178 218  
Radiotherapy: 
Time Surgery to Chemotherapy (CT) (days) 101/102 203 133 
Time CT to Radiotherapy (RT) (days) 102/102 204 20 
Trial Arm (control or test) 72/146 218  
 
Table 11: Patient and treatment characteristics. Characteristics have been categorised according to the information they provide. Median 
values are given for continuous characteristics. 
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Table 11 shows how the data were divided within each patient, surgical or treatment related 
characteristic. For continuous characteristics the data were dichotomised above and below the 
median value. For each of the characteristics, differences between population systematic 
errors between the groups were tested.   
 
Statistical analyses: Data were tested for normality using Shapiro-Wilk test.  Fisher‟s F-test, 
or the Levene‟s test were used to test for the significance of any difference in the variance of 
population systematic errors for both laser and bony anatomy set-up (laser, bone). Where the 
data were non-normal the Non-Parametric Levene‟s Test was used. Significance testing was 
performed with and without adjustment for multi-testing (Holm-Bonferrroni method). 
Associations between characteristics which gave significantly different systematic errors 
were investigated using Wilcoxon and Kruskal-Wallis tests.  
 
 
Results 
 
A total of 1574 images were analysed to provide the set-up data. There was a minimum of 5 
images per patient.   
 
Table 12 presents results for the laser based set-up – only results where differences were 
statistically significant are given. Of the ten characteristics investigated 3 showed a statistical 
significant difference between the laser based systematic set-up errors laser. One of these was 
a patient characteristic (breast volume) and the other two were surgical characteristics 
(closing technique and seroma visibility).  On application of Holm-Bonferroni correction, 
only seroma visibility gave a statistical difference between patient groups (in the AP and SI 
directions).  The largest difference in laser, of 1 mm, was for the breast volume; all other 
differences were < 1mm. Differences in laser for breast volume were significant only in the 
superior-inferior (SI) direction. No association between breast size, tumour bed position, 
seroma visibility and surgical closing technique was found.  
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Table 13 gives the results for the bony anatomy based set-up, again only for characteristics 
where differences were statistically significant.   There were only 2 characteristics were this 
was the case, both were patient related: breast volume and tumour bed axial position. Both 
characteristics gave significant differences when Holm-Bonferroni correction was applied, 
although TB axial location no longer affected set-up error in the LR direction.  All 
differences in population systematic error, bone were < 1mm. Again, breast volume 
differences were significant in the SI direction and neither of the other directions.  
 
No radiotherapy characteristics, clip placement or number, or tumour bed superior-inferior 
position were related to population systematic set-up errors in this study. 
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Characteristic Group 1  laser 
(cm) 
Group 2  laser 
(cm) 
p-value Direction and 
magnitude of 
difference in ∑ 
(cm) 
Breast volume  < 855cm
3
 0.25 ≥ 855 cm3 0.32 0.03 SI      0.07 
Seroma Visibility not visible/subtle 0.28 easily visible 0.35 0.02 LR     0.07 
 not visible/subtle 0.26 easily visible 0.32 0.002 SI      0.06 
 not visible/subtle 0.31 easily visible 0.41 0.005 AP     0.10 
Surgical Closing technique closed 0.27 open 0.33 0.02 LR     0.06 
 closed 0.25 open 0.32 0.04 SI    0.07 
 
Table 12: Systematic (laser) laser set-up (no imaging) errors for patients grouped using patient and treatment related characteristics.  For laser, 
P-values from the non-parametric Levene’s test are given. Values are only shown for characteristic that gave a significant difference between 
patient groups (p<0.05, without Holm-Bonferroni adjustment). The directions in which differences occur are indicated (SI denotes superior-
inferior, LR denotes left-right and AP denotes anterior-posterior). 
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Characteristic Group 
1 
BA 
(cm) 
Group 2 BA 
(cm) 
p-
value 
Direction and 
magnitude of 
difference in ∑BA (cm) 
TB Axial 
Location 
1,2 and 
3 
0.21 4 0.27 0.04 LR  0.06  
TB Axial 
Location 
1 0.16 2, 3 and 4 0.23 0.002 AP 0.07 
Breast volume <855 
cm
3
 
0.19 ≥855cm3 0.27 0.015 SI  0.08 
 
Table 13: Systematic standard imaging set-up errors  (BA) for patients groups determined 
using patient and treatment related characteristics.  P-values for non-parametric Levene’s 
test are given. Data only given for characteristic that gave a significant difference in 
systematic bony anatomy verification error between patient groups (p<0.05, without Holm-
Bonferroni adjustment).  The direction in which errors were different is indicated. 
 
Discussion 
 
The purpose of this work was to identify whether a set of patient and treatment variables 
influence set-up errors, and to explore the feasibility of individualised TB PTV margins in 
breast boost radiotherapy using no imaging or standard imaging. The study has shown that 
two patient characteristics (breast volume and TB axial location) and two surgical 
characteristics (closing technique and seroma visbility) affect laser and bony anatomy based 
set-up accuracy. No radiotherapy characteristics were found to have a significant effect on 
set-up errors.  
 
Population systematic errors for both laser and bony anatomy set-up (laser and BA) were 
greater (by 2mm and 1 mm) for patients with a breast volume greater than 850 cm
3
 but this 
was only statistically significant for the SI direction of movement. This may be because 
breast tissue moves more independently of bony anatomy and skin based tattoos in larger 
breast women.  Hasan et al.
9
 had previously reported a weak correlation between the mean 
patient set-up error, measured using upon bony anatomy, and breast volume (n=27 and p = 
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0.02). They did not investigate, however, the association of the population systematic set-up 
error with breast volume as we have done in this work.   
 
If patients are set-up at the time of treatment with lasers matched to skin marks, then those 
patients with easily visible seroma and open surgical cavities have a statistically significantly 
increased population systematic error, although this is small in magnitude (0.6 to 1.0 mm 
depending of the direction of movement).   It is possible that this increase is due to changes in 
the location of the clips between the planning CT scan and treatment due to shrinking seroma 
or clip migration
106
.  If this were the case, then BA would also be affected by seroma 
visibility and surgical closing technique.  A greater value for BA was not observed which 
indicates that the observed differences in laser are probably not due to changes in clip 
location.  
 
If patients are set-up using standard imaging, we found that population systematic errors were 
influenced by the tumour bed location. Patients with medially located tumour beds had 
smaller BA in the AP direction, while patients with laterally located TBs had larger BA in 
LR direction by 0.6 and 0.7 mm respectively.  It is likely that there is little movement of 
medial breast tissue compared to bony anatomy and greater movement of lateral breast tissue 
which may explain these results. This is also supported by Hasan et al.
9
 who found 
correlation of 3D bony anatomy verification errors with distance from the chest wall (p = 
0.003).  Similarly, Topolnjak et al.
93
 showed that the distance of the TB from the chest wall 
was correlated with the difference between TB set-up error for chest wall and the breast 
surface (r = 0.476, p = 0.034).  
 
All differences in population systematic error were small < 1mm, however, these systematic 
errors make the greatest contribution to tumour bed PTV margins (PTV margin = 2.5 + 
0.393).  The largest difference in systematic errors (1 mm) was observed with a laser based 
set-up in the AP direction between patients with easily visible or not visible seroma   (laser = 
0.31 cm for smaller breasted patients compared to laser = 0.41 for larger breasted patients).  
This gives a difference in PTV margin of 2.5 mm and indicates larger margins for patient 
with large seroma may be appropriate for laser-based set-up. All others changes in margins 
were estimated to be 2 mm or less.  
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This study used univariate analysis to identify several variables which may be used to group 
patients with smaller or larger systematic errors.  A limitation of this study is that no 
multivariate analysis has been employed. However, no standard multivariate statistical model 
was identified which was suitable to test the interaction of multiple variances.  Care should be 
taken when interpreting p-values, presented in tables 12 and 13, as these have not been 
adjusted for multiple testing. Using, one method to control false positive results, Holm-
Bonferroni correction, differences between patients grouped using seroma visibility and TB 
axial position remain significant. A further limitation of our study may be the use of only one 
observer to grade seroma visibility. In Lee et al.
107
, seroma visibility in 20 patients was 
scored by radiation oncologists and radiographers using the Clarity Visualisation Score 
(CVS) which grades seroma visibility on a scale of 1 to 5.  There was a 0.2 difference in the 
median grade between the two groups (3.8 v. 3.6). Amongst radiation oncologists, all grades 
agreed with median CVS agreed within 1 grade except in 1 of 20 cases. These variations 
amongst observers are small and it is expected would be smaller still if only two ranks are 
used, as is the case in our study. Consequently, we expect any observer error to be small.  
Furthermore, to minimise intra-observer error, the radiation oncologist (MM) scoring seroma 
used a pre-defined protocol and has previously outlined/scored seroma visibility on nearly 
800 patients (Mukesh et al.
108
). 
 
 
The consequences of small changes in PTV margins have been investigated and are described 
in Chapter 6. Reductions in margins may reduce the dose to normal tissues such as heart and 
lungs. Darby et al.
109 
have recently reported evidence a zero threshold for cardiac toxicity so 
even small changes in mean heart dose are of importance given the large numbers of patients 
receiving radiotherapy for breast cancer. 
 
Conclusions 
 
Patient and surgical related characteristics have limited affect on population systematic errors 
derived from laser based (no imaging) and bony anatomy (standard imaging) set-up methods. 
Four groups have been identified who may benefit modestly from reduced PTV margins: 
women with breast volume of < 850 cm
3
, those with invisible/subtle seroma, closed cavities 
or medial tumour bed locations.
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Chapter 6 – The Impact of Image Guidance on Dose Distributions in Breast Boost 
Radiotherapy 
 
This work described in this chapter investigates the decrease in normal tissue irradiated to 
95% of the breast boost dose if standard imaging is used, compared to clip-based IGRT, a 
secondary research objective of this study. It also investigates the effect of clip-based IGRT 
on dose to the heart and lungs, and the effect of IMPORT high trial arm on the volume of 
tissue spared.   
 
Introduction 
 
Whole breast irradiation (WBI) following breast conserving surgery is a standard treatment 
for patients with breast cancer. As part of their radiotherapy, patients at high risk of 
recurrence receive a boost dose to the region around the tumour bed
110
. Evidence shows that 
accurate localisation of the tumour bed can only be achieved if internal markers are used to 
indicate its position on imaging, particularly CT images
111,112
. This approach to improve 
localisation allows conformal photon dose distributions to be used to deliver the tumour bed 
boost dose whilst minimising dose to normal tissues. This further enables studies of dose 
escalation using sequential or integrated boost techniques
57,113
. 
 
Accurate patient set-up and in-treatment verification is essential for the delivery of conformal 
radiotherapy and higher boost doses. As discussed in the two previous chapters, standard 
verification imaging for breast radiotherapy uses bony anatomy and often the outline contour 
of the breast to match electronic portal images acquired at megavoltage energies (MV) to pre-
treatment images – often digitally reconstructed radiographs. This is widely available and 
requires a surrogate for the tumour bed, such as the patient‟s ribs, as neither the tumour bed 
nor implanted surrogate markers are visible on MV images. Gold markers are visible on MV 
images and have been demonstrated in this setting, but are not widely used surrogates
94
. 
Kilovoltage energy imaging is necessary to visualise surgical clips, hence determining 
tumour bed positions most accurately and bringing the potential to decrease tumour bed 
Planning Target Volumes (PTV).  
 
Previous studies have shown that 5 mm tumour bed PTV margins of 5 mm can be 
achieved
94,114
 using IGRT. The purpose of the work in this chapter was to evaluate the 
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dosimetric impact in terms of doses to breast tissue and organs at risk as a result of the use of 
IGRT and the reduced margins it allows in breast boost radiotherapy. 
 
 
Materials and Methods 
 
The CT data sets, used for treatment planning, for patients treated in the IMPORT HIGH trial 
were selected sequentially form an alphabetical ordered list. The patients were treated 
between July 2009 and December 2011. As discussed above, the patients had surgical clips 
implanted close to the tumour bed at during breast conserving surgery (BCS). Two target 
volumes were defined. Firstly a Clinical Target Volume (CTV) was defined for the tumour 
bed (CTV_TB). This encompassed the surgical clips, plus any seroma and architectural 
distortion. Secondly a target volume for the whole breast (WB_TV) was defined from the 
extent of the treatment fields for the whole breast. This excluded the lung and ribcage and 
tissue within 5 mm of the surface of the skin. On the treatment plans, organs at risk were 
delineated. These were: the ipsilateral lung, contralateral lung, heart and contralateral breast.  
 
The CTV_TB structure was expanded to create two Planning Target Volumes (PTV_TB) for 
each data set as shown in figure 13: the first using a 5 mm margin as required by IMPORT 
HIGH. We have previously described
94,114
 how the use of image guidance based on imaging 
the positions of markers implanted in the tumour bed, coupled to set-up correction strategies 
reduces population set up errors to the extent that a 5 mm tumour bed PTV margin may be 
achieved. The second PTV_TB margin was 8 mm and was derived from the analysis 
presented in chapter 4 for bony anatomy based set-up measurement. Systematic errors in 
patient set up were determined based on measurements from images of the first 3 fractions 
and a correction applied on fraction 4. This approach enabled a comparison between standard 
bony anatomy based verification and the IGRT approach. 
 
30 patients were planned using a sequential, conformal photon boost to the tumour bed and 
30 using the simultaneous integrated boost (SIB) technique. The sequential boost technique 
delivered a phase 1 WBRT dose of 40 Gy in 15 fractions followed by 16 Gy in 8 fractions to 
the tumour bed boost volume only for phase 2. The concomitant boost technique involved 
delivering 15 fractions with a total dose 36 Gy to the whole breast using tangential fields; 
plus 40 Gy to the partial breast volume and an escalated dose to the tumour bed via co-planar 
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conformal fields. The escalated dose was 48Gy or 53Gy (15 patients each) depending on 
randomisation
57
 (see figure 2). The criteria for plan assessment and constraints on the organ 
at doses used for the IMPORT HIGH trial were used to guide the planning (Table 14). Plans 
were generated using the Philips Pinnacle
3
 (Philips Medical System, Netherlands) treatment 
planning system (v8.0 and v9.0). The forward treatment planned method reported by 
Donovan et al.
115
 was used, with the collapsed cone convolution dose calculation algorithm 
on a 0.25 cm  0.25 cm  0.25 cm calculation grid. The beam quality used was 6MVin most 
cases. 
 
 
 
Figure 13: section through a patient’s treatment plan showing CTV_TB (red),  PTV_TB = 5 
mm (yellow) and PTV_TB = 8 mm (pink). 
 
Statistical Analysis: For the analysis of the treatment plans produced to determine the impact 
of IGRT on the breast boost plans, the main metric used was the volume of tissue receiving 
95% of the tumour bed dose.  Data were also collected on the doses to the lungs, heart and 
contralateral breast from the plan assessment criteria listed in Table 14. Mean heart and lung 
doses were also collected. The data were tested for normality. The Wilcoxon signed ranks test 
was used to test for statistical significance of the differences in the various metrics between the 
plans with 5 mm and 8 mm PTV_TB margins. Data were dichotomised by tumour bed laterality 
and the Mann-Whitney test statistic was used to determine the significance of any differences 
observed.  
 119 
 
 
This work is novel and there were no similar studies in the literature on which to base 
estimates for sample size calculations. The heart is one of the most important organs at risk in 
breast radiotherapy. The results from planning the first ten cases were used to estimate a 
sample size of 58 cases, which gave 90% power to determine a difference of 0.2Gy at a 
significance level of 0.05. The additional cases were included to allow for any unforeseen 
problems with the data.  
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 Sequential Boost  
 Minimum Dose Median Dose Maximum Dose 
Whole breast 
 
> 90% volume > 36 Gy 40 to 44 Gy  < 5% volume > 56 Gy 
Tumour bed PTV > 95% volume > 53.2Gy 
 
55.5 to 56.5 Gy < 5% volume > 60 Gy 
 Concomitant Boost 
 Minimum Dose Median Dose Maximum Dose 
Whole breast  
 
> 90% volume > 32.4 Gy 34 to 37 Gy  < 5% volume > 40 Gy 
Partial breast PTV 
 
> 90% volume > 36 Gy 40 to 44 Gy   
 
Tumour bed PTV 
 
> 95% volume  
>45.6Gy or 50.4Gy 
47.5 to 48.5 Gy or 
52.5 to 53.5 Gy 
< 3% volume  
> 51.4Gy or 56.7Gy 
 
 Organs at Risk  
 Dose (Gy) Maximum Allowed Volume (%) 
Ipsilateral Lung 18 15 
Contralateral Lung 2.5 15 
Heart 13 10 
Contralateral 
Breast 
Mean Dose < 0.5Gy Permitted Maximum Mean Dose 1.5 Gy 
 
Table 14: Radiotherapy treatment planning constraints for IMPORT HIGH. Bold indicates 
mandatory constraints. Where two dose levels are given they are for the 48Gy or 53Gy test 
arm doses. 
 
Results 
 
Of the patients recruited to this study, 35 had left breast disease and 25 had right breast 
disease. The median CTV_TB volume was 10.2 cm
3
 (range 2.4 – 205.0 cm3). There was no 
statistical significant difference in the CTV_TB or PTV_TB volumes (grouped into 5mm and 
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8 mm margins) between the sequential and concomitant boost plans, or the concomitant boost 
plans at boost doses of 48 Gy or 53 Gy.   
 
Table 15 summarises the volumes of breast tissue and the percentage of whole breast volume 
receiving 95% of the dose prescribed to the tumour bed. There was a statistically significant 
difference (p < 0.01) between the volumes of breast tissue receiving a high dose for the two 
types of plan, with the volumes larger in the sequential boost plans. The magnitude of the 
volume changes between a PTV_TB of 5 mm and a PTV_TB of 8 mm was not different 
between: i) sequential and concomitant boost plans; ii) between left and right breast plans; 
and iii) between the 48Gy and 53Gy boost doses. The difference data for sequential and 
concomitant boost treatments were combined and the median decrease in the high dose 
volume, for IGRT was found to be 29 cm
3
 (range 11 to 193 cm
3
). This equates to an 
additional 3.3% (median value) up to a maximum of 11.8% of the whole breast volume 
spared high dose irradiation from these boost techniques, if clip-based IGRT is used. 
 
All dose metrics for the organs at risk increased with the use of the 8 mm margin for standard 
verification, compared to the IGRT margins. This was as anticipated and a modest effect 
(table 16). Of the various metrics, only mean heart dose and V13Gy for the heart had a 
statistically significant relationship with tumour bed laterality (p < 0.01); with higher values 
in the left breast group.   
 
In the case of the IGRT margins of 5 mm, 56 of the 60 cases met all the treatment planning 
criteria (table 14). The minimum dose coverage of the tumour bed was between 91% and 
95% in the other four cases (2 sequential and 2 concomitant boost). These were all left breast 
cases and had the tumour bed in close proximity to the chest wall, hence the PTV_TB 
extended into lung and the heart (see figure 14). Thus a compromise was accepted between 
target coverage and heart dose for the clinical treatment. Also, in one of the two concomitant 
boost cases that failed the planning criteria, the maximum volume limit for the highest dose 
to whole breast was exceeded (9.7% compared with 5%). This patient had a large CTV_TB 
of 49 cm
3
 whereas the median CTV_TB volume for the patients in the study was 9 cm
3
, 
hence the difficulty in obtaining a dose distribution that meet all of the treatment planning 
requirements.   
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As the planning objectives used in IMPORT HIGH were based on a PTV_TB margin of 5 
mm, it was likely that increasing this margin to 8 mm would cause more plans to fail the 
criteria. This was found to be the case with four sequential boost plans and 10 concomitant 
boost plans breaching mandatory planning constraints. In all the sequential boost cases and 
eight of the concomitant cases, the PTV_TB coverage was below 95% but above 91%.  In 
three of the concomitant boost cases, the maximum dose criterion in the whole breast volume 
was exceeded by 2% in two cases and 5% in the third. In nine of the concomitant boost cases 
the median dose constraint to the partial breast volume of 40 to 44 Gy was exceeded by 
between 0.5Gy and 3.7 Gy. 
 
Table 15: Volumes of the breast receiving 95% of prescribed dose from plans based on 
5 mm and 8 mm PTV_TB margins. Data are given as median (range) and presented in 
absolute volume (cc) and as a percentage of the whole breast volume. Differences 
between 95% volumes for the two PTV_TB were statistically significant (p<0.01) and 
are given in column 4. 
 
 PTV_TB = 5mm PTV_TB = 8mm Difference 
High dose Volume (cc)    
Sequential boost 91 (30 – 863) 125 (42 – 1005) 33 (11 - 193) 
Concomitant boost 60 (19 -  228) 87 (30 – 260) 23 (11 - 66) 
Both combined 69 (19 - 863) 100 (30 – 1005) 29 (11 - 193) 
Percentage of whole 
breast volume (%) 
   
Sequential boost 10 (4 – 35) 14 (5 - 41) 4 (2 – 12) 
Concomitant boost 8 (2 – 19) 11 (4 – 24) 3 (1 – 6)  
Both combined 3.0 (1 – 6) 4 (2 – 12) 3 (1 – 12) 
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Figure 14: A) shows an original PTV_TB with 5 mm margin and in close proximity to the 
lung. When PTV_TB is increased by a further 3 mm it expands into the lung B) and to 
achieve coverage requires an increase in the width of the tangential fields  by 4 mm C) which 
in turn increasing the dose to heart. 
 
A 
B 
C 
 124 
 
 PTV_TB = 5 mm PTV_TB = 8 mm Difference 
Ipsilateral lung V18Gy (%) 
 
9.6 (1.9 - 27.6) 10.0 (2.3 - 27.8) 0.3 (-0.9 - 5.0) 
 
Ipsilateral lung mean dose 
(Gy) 
 
5.6 (2.6 - 11.3) 
 
6.1 (2.8 - 11.5) 
 
0.3 (-0.7 - 2.7) 
 
Contralateral lung V2.5Gy 
(%) 
Sequential boost 
Concomitant boost 
 
 
0.0 (0.0 - 12.2) 
1.6 (0.0 - 13.4) 
 
 
 
0.1 (0.0 - 13.9) 
3.2 (0.0 - 17.4) 
 
 
0.0 (-3.3 - 7.5) 
1.0 (-2.5 - 16.1) 
Contralateral lung mean 
dose (Gy) 
 
0.4 (0.1 - 1.2) 
 
0.5 (0.1 - 3.3) 
 
0.1 (-0.2 - 3.1) 
 
Contralateral breast mean 
dose (Gy) 
 
5.0 (0.0 - 1.8) 5.0 (0.0 - 1.4) 0.1 (-1.3 - 0.4) 
Heart mean dose (Gy) 
Right breast cases 
Left breast cases 
 
1.2 (0.4 - 2.2) 
1.9 (0.6  - 5.1) 
 
1.4 (0.5 - 2.6) 
2.1 (0.6 - 6.0) 
 
0.2 (-0.3 - 1.6) 
0.2 (-0.2 - 1.0) 
 
Heart V13Gy (%) 
Right breast cases 
Left breast cases 
 
0.0 (0.0  - 0.0) 
0.2 (0.0 - 5.5) 
 
0.0 (0.0 - 0.2) 
0.4 (0.0 - 6.3) 
 
0.0 (0.0 - 0.2) 
0.1 (-0.1 - 2.4) 
 
Table 16: Dosimetric data given as median (range) for each of the assessment criteria. All 
differences were found to be statistically significant (p< 0.01). 
 
Discussion 
 
The work presented in this chapter evaluated the impact of IGRT on normal tissue doses in 
breast radiotherapy. We have seen in the two previous chapters that IGRT enables smaller 
PTV margins due to the reduction of set-up errors across the patient population. The reduced 
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margins achievable with the use of internal markers (and associated image guidance) led to a 
reduction of 29 cm
3
 (range 11 – 193 cm3) in the volume of breast tissue receiving a high 
dose. This is a consequence of the ability to reduce the PTV_TB margin from 8 mm to 5 mm. 
 
 
In chapter two we discussed the evidence for a dose/volume relationship for normal tissue 
toxicity in breast tissue. This is still an open question and the dose/volume constraints needed 
are still a subject of research
116
. Hence it is unclear what outcome effect is expected at the 
dose levels and volumes reported in this chapter. In the EORTC study of Bartelink et al.
2
 they 
reported that an WBRT dose of 50 Gy followed by a boost dose of 16 Gy, the 10 year risk of 
fibrosis increased  by approximately 15% from 13.2% (for the no boost group) to 28.1% (for 
the boost group). Patients in this study were treated with a PTV margin of 15 mm compared 
to the much smaller values of 5 and 8 mm discussed here. The sequential boost prescription 
used in this study was 16 Gy in 2 Gy fractions and hence is expected to lead to a lower rate of 
fibrosis that than in the EORTC study, due to the smaller high-dose volumes.  
 
The larger PTV_TB margin had modest impact on the calculated doses to organs at risk for 
both types of boost plans: sequential and concomitant. The majority of the therapeutic dose 
was delivered using standard tangential fields, which maintained organ at risk sparing in 
these complex situations for all PTV_TB margins. The recent cardiac risk study of Darby et 
al.
109
 suggests that small changes in heart dose are important as a consequence of the linear 
relationship between mean heart dose and Major Coronary Events (MCE). Hence given the 
tens of thousands of women treated each year with radiotherapy for breast cancer, a modest 
reduction in heart dose may impact significantly on the rate of MCE in the survivor 
population. 
 
One finding of this study was the increased difficulty in meeting the planning requirements 
for the boost which an increase in the PTV_TB margin of only 3 mm. This had most impact 
for the concomitant boost plans where one in three patients failed at least one of the 
dosimetry criteria.  
 
The compromised median dose to the partial breast in nine cases is particular relevant for the 
IMPORT HIGH trial which requires discrimination between the three dose levels of the 
whole breast, partial breast and tumour bed. This work shows that image guidance is 
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necessary to achieve this level of dose discrimination: an additional benefit to reduced normal 
tissue doses. 
 
Conclusions 
 
The reduction in normal tissue irradiated when using clip-based IGRT was modest (29 cm
3
). 
For breast radiotherapy methods involving a complex boost technique, image guidance is 
important as it allows the dose levels to be sufficiently discriminated. Its use allows some 
reduction in the dose to breast, heart and lung for both sequential boost and concomitant 
boost approaches.    
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Chapter 7 – Discussion and conclusions 
 
 
The previous five chapters have summarised the key outcomes of this Efficacy and 
Mechanism programme. The chapters have been grouped by the key stages of the 
programme. Chapter 2 and 3 discuss the evidence for a dose volume effect in breast 
radiotherapy following BCS. Chapters 4, 5 and 6 discuss the evaluation of IGRT in this 
setting.  
 
The critical review in chapter 2 explored the evidence in the literature for a dose volume 
effect in normal breast tissue. The review found differing results from studies addressing the 
relationship between irradiated breast volume and late breast tissue complications. For 
example, Borger et al reported strong evidence for a volume effect.
14
. They found that for 
every 100 cm
3
 increase in the boost volume, the risk of fibrosis increased by a factor of four 
and that a two-fold increase in boost volume results in an 11% reduction in tolerance dose 
(NTD50). Borger‟s study used low dose rate iridium brachytherapy implants, which produce a 
very high dose region within the implant and rapid fall off of dose outside the implant. The 
other studies discussed in chapter 2 include partial breast irradiation (PBI) and intra-operative 
radiotherapy (IORT) trials and matched case series that compared PBI with whole breast 
irradiation (WBI). Whilst these other studies generally suggested some evidence of a 
relationship between volume irradiated to high dose and normal tissue complication 
probability (NTCP), they did not quantify the volume effect. The brachytherapy and intra-
operative dose distribution can differ from the external beam radiotherapy (teletherapy)  and 
therefore, it is unclear whether these results can be extrapolated to external beam  
techniques.. There are several ongoing external beam radiotherapy breast trials that are 
designed to provide further data in this direction: IMPORT LOW
56,57
 and the Danish Breast 
Cancer Cooperative Group trial
62
 are trials which compare PBI with WBI and IMPORT 
HIGH
56,57
 is investigating the effects of three dose regions throughout the breast using 
intensity modulated radiotherapy (IMRT) for dose delivery, imaged with clip-based IGRT.
 
 
In chapter 3, we addressed a secondary research objective of this study: to estimate the 
reduced risk of late adverse effects resulting from the smaller tissue volume irradiated, using 
data generated and published from earlier randomised trials conducted by members of our 
collaboration. 
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Individual patient data of 5856 patients from the Cambridge trial
66,72
 and EORTC trial
66,72
 
were used for the analysis with moderate-severe breast fibrosis as the radiotherapy toxicity 
endpoint. Fits to the data using two standard models of NTCP (the LKB
74
 and Niemierko
75
 
models) produced a volume parameter „n‟ close to zero, suggesting that for moderate and 
severe fibrosis, the breast acts as an organ with serial structure (as discussed in chapter 3). 
These results were successfully validated on an independent dataset and indicated that for 
moderate-severe breast fibrosis, the maximum radiotherapy dose is the most important 
parameter rather than volume of tissue irradiated. Based on this model, a change in volume of 
normal tissue irradiated will not change the risk of breast fibrosis. Clearly, any model has 
limitations and the mature results from the clinical trials addressing this question are awaited.  
 
In chapter 4, we addressed the primary research objective of this study, namely the difference 
in accuracy of clip-based IGRT and standard imaging using bony anatomy. We also 
addressed two secondary objectives: 1) the reduction in safety planning target volume (PTV) 
margin, and 2) the time required for clip-based IGRT and standard imaging. We presented 
results of the analysis of the impact of clip-based IGRT on set-up errors and treatment 
margins in patients recruited to the IMPORT HIGH study. To our knowledge this is the 
largest study to evaluate IGRT in the breast radiotherapy setting. This study found that clip-
based IGRT was more accurate than standard imaging. The population systematic error was 
between 2 to 4 mm greater with standard imaging. A key finding of the study was that a PTV 
boost safety margin of 5 mm is sufficient if clip-based IGRT is employed. The clip-based 
IGRT approach was based on imaging the positions of titanium clips implanted in the tumour 
bed at time of breast conserving surgery (BCS). In contrast, standard imaging using bony 
anatomy required an 8 mm PTV boost safety margin and no imaging (i.e. set-up based on 
laser-based alignment of the patient surface) required a 10 mm margin. These results indicate 
that for patients receiving concomitant tumour bed boost, a margin less than 8mm cannot be 
safely used without clip-based IGRT as there is a risk of geographical miss of the tumour bed 
being treated within the high dose region. The difference in time required to perform clip-
based IGRT and standard image assessment was technique dependent. Clip-based IGRT was 
quicker than standard imaging when using 2D-KV technique, but not when using cone beam 
CT imaging. 
 
Chapter 5 explored the factors influencing the primary objective. It tested the hypothesis that 
some characteristics of the patient and treatment may influence: i) the relationship between 
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the set-up error measured with IGRT and with bony anatomy imaging (standard imaging), 
and ii) the relationship between the set-up error measured with IGRT and with laser-based 
alignment (no imaging). Patients with larger breasts required a larger PTV margin for both 
standard imaging and no imaging. Seroma visibility and surgery technique both affected no 
imaging set-up errors, whereas tumour bed position affected g standard imaging based set-up 
errors. The work implies that clip-based IGRT may be of greater benefit compared to 
standard imaging or no imaging, for some patient groups and that treatment margins can be 
modified accordingly if clip-based IGRT is not available. 
 
Chapter 6 evaluates the reduction in volume of normal tissue receiving 95% the high boost 
dose of radiation when clip-based IGRT is used compared with standard imaging, which is a 
secondary objective of this study. The consequences of the results of the IGRT study on 
treatment planning were evaluated. The main quantitative finding was that the use of clip-
based IGRT allowed the volume of breast tissue irradiated to a high dose to be reduced by 29 
cm
3
 (with a range of 11 to 193 cm
3
) for the 60 cases studied. The use of smaller PTV margins 
with clip-based IGRT also allowed a small reduction in the radiotherapy dose to the 
contralateral breast, heart and lung. The larger margins needed with standard imaging meant 
that the treatment planning constraints for the dose boost could not be met in some cases. 
 
In conclusion, this research demonstrates the benefits of clip-based IGRT over standard 
imaging, with a reduction in PTV margins. Margins less than 8 mm cannot be safely used 
without clip-based IGRT for patients receiving concomitant tumour bed boost as there is a 
risk of geographical miss of the tumour bed being treated within the high dose region. In 
principle, these smaller, but accurately placed margins may influence local control rates, but 
this needs to be evaluated from mature clinical trial data in the future. We have not been able 
to develop a model that can predict the effect of irradiated volume on breast tissue toxicity, 
but mature results from the ongoing clinical trials may provide a definitive answer. 
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